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WITNESS SEMINARS:
MEETINGS AND PUBLICATIONS1
In 1990 the Wellcome Trust created a History of Twentieth Century Medicine
Group, as part of the Academic Unit of the Wellcome Institute for the History
of Medicine, to bring together clinicians, scientists, historians and others
interested in contemporary medical history. Among a number of other
initiatives the format of Witness Seminars, used by the Institute of
Contemporary British History to address issues of recent political history, was
adopted, to promote interaction between these different groups, to emphasize
the potential benefits of working jointly, and to encourage the creation and
deposit of archival sources for present and future use. In June 1999 the
Governors of the Wellcome Trust decided that it would be appropriate for the
Academic Unit to enjoy a more formal academic affiliation and turned the
Unit into the Wellcome Trust Centre for the History of Medicine at University
College London from 1 October 2000. The Wellcome Trust continues to fund
the Witness Seminar programme via its support for the Centre.
The Witness Seminar is a particularly specialized form of oral history, where several
people associated with a particular set of circumstances or events are invited to
come together to discuss, debate, and agree or disagree about their memories. To
date, the History of Twentieth Century Medicine Group has held nearly 40 such
meetings, most of which have been published, as listed on pages xi–xviii.
Subjects are usually proposed by, or through, members of the Programme
Committee of the Group, and once an appropriate topic has been agreed,
suitable participants are identified and invited. This inevitably leads to further
contacts, and more suggestions of people to invite. As the organization of the
meeting progresses, a flexible outline plan for the meeting is devised, usually
with assistance from the meeting’s chairman, and some participants are invited
to ‘set the ball rolling’ on particular themes, by speaking for a short period to
initiate and stimulate further discussion. 
Each meeting is fully recorded, the tapes are transcribed and the unedited
transcript is immediately sent to every participant. Each is asked to check his
or her own contributions and to provide brief biographical details. The editors
turn the transcript into readable text, and participants’ minor corrections and
comments are incorporated into that text, while biographical and
bibliographical details are added as footnotes, as are more substantial
comments and additional material provided by participants. The final scripts
are then sent to every contributor, accompanied by forms assigning copyright
to the Wellcome Trust. Copies of all additional correspondence received
during the editorial process are deposited with the records of each meeting in
Archives and Manuscripts, Wellcome Library, London.
As with all our meetings, we hope that even if the precise details of some of the
technical sections are not clear to the non-specialist, the sense and significance
of the events will be understandable. Our aim is for the volumes that emerge
from these meetings to inform those with a general interest in the history of
modern medicine and medical science; to provide historians with new insights,
fresh material for study, and further themes for research; and to emphasize to
the participants that events of the recent past, of their own working lives, are
of proper and necessary concern to historians.
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INTRODUCTION
All too often, especially in popular accounts of medical history, significant
medical advances seem to arrive effortlessly as if they were the obvious and
inevitable next steps in a research process that had a clear fix on exactly how to
get to the desired goal. Serious historical scholarship has revealed that, most
often, this is definitely not the case. Dogged determination at the lab bench is
affected by chance occurrences, setbacks, charismatic or conflicting
personalities, and dozens of other factors which intervene and interconnect to
create a complex dynamic as the research proceeds.
On 3 June 2003, a Wellcome Witness Seminar was convened to examine what
certainly qualifies as one of the major medical advances of the twentieth
century: the prevention of rhesus haemolytic disease – or erythroblastosis
fetalis – in newborns. This disease can arise when there is an immunological
clash between Rh-negative mothers and their Rh-positive fetuses. When such
a clash occurs, it exacts a terrible toll. Over a period of only about 30 years,
from roughly the 1940s to the 1970s, the basis of this life-threatening disorder
was understood, treatments were perfected, and a highly successful means of
prevention was developed and validated. Despite our familiarity with the
general outline of this story, most of the details – the back story as it were –
are not known. This Witness Seminar was organized to fill in the knowledge
gaps and gain a clearer understanding of the way this significant achievement
in medical science came about.
The transcript that follows is the complete record of the discussions at this
Witness Seminar. It covers the first experiments with Rh typing, the exchange-
transfusion and intrauterine-transfusion procedures developed by clinicians to
treat affected newborns and fetuses, and the research efforts that ultimately
produced a prevention in at-risk families.
The ‘Rhesus Factor and Disease Prevention’ Witness Seminar was also the
occasion for laying to rest a controversy that had arisen among medical
historians and science writers as they tried to understand the history of rhesus
disease prevention. The lingering controversy involved the question: Who was
the first person to suggest that anti-Rh antibody could be used to remove Rh-
positive cells and prevent the sensitization of the Rh-negative mothers? Was it
Ronald Finn, the physician/researcher who presented the idea at a meeting of
the Liverpool Medical Institution? Or was it, as Cyril Clarke maintained,
Clarke’s wife and research assistant, Féo, who woke him one night saying,
1 Clarke (1968).
2 A very brief account of the prevention of Rh haemolytic disease is given in a recording of Professor
Philip Sheppard, 18 March 1968, available in the Genetics Society Archive (1968; SID I, 1–180),
John Innes Centre Archives, Norwich.
‘Give them (the Rh-negative mothers) anti-Rh’ (page 40)1 Even Philip
Sheppard, Clarke’s close colleague, was uncertain. In an interview (c. 1968)
captured on audiotape and available at the John Innes Centre Archives,2 he said
only that it was Clarke who first mentioned the idea to him. At this Witness
Seminar, Professor Ronald Finn offered an answer that appears to resolve the
controversy (page 40 and note 93a).
In addition, the participants were able to bring the history up to date, showing
how it influenced the development of the new fields of neonatal and fetal
medicine, and identifying areas of the rhesus story that still pose challenges
both in the laboratory and in the clinic.
There is much that we can learn from the discussions and each reader will surely
come away better informed, albeit in different ways. There are, however, a few
elements that we would like to highlight here – elements not usually recognized
in the popular accounts – that not only contributed to the successful conclusion
of this episode in medical history but that may also hold some lessons for
investigators and funding agencies working in today’s research environment:
• Although individuals around the world were working hard to improve the
condition of the newborns and reduce the suffering of their families, there
does not appear to have been a race in which various people or groups vied
to become the victor. Instead, one hallmark of this far-flung research
community was the spirit of cooperation that extended to the sharing of
ideas, reagents, data, and experience as people worked to provide better
modes of treatment and to achieve a means of prevention.
• Another feature that emerged in the discussions was the number of
collaborations that arose, particularly those in which the collaborators had
strikingly different training, areas of expertise, or worked in different types
of institutional settings. The most prominent example is the collaboration
that arose between Cyril Clarke (1907–2000), a physician in Liverpool, and
Philip Sheppard (1921–76), an ecological geneticist working at Oxford. This
partnership, initiated by their mutual interest in butterflies, soon involved
joint work on projects in an area that was new to both of them: medical
genetics. Ultimately, they extended their research agenda to include rhesus
xx
haemolytic disease.  There were a number of other collaborations as well –
such as with the Blood Transfusion Service, the medical genetics laboratory
(under the direction of Victor McKusick) at Johns Hopkins University in
Maryland (USA), researchers at the Ortho Pharmaceutical Corporation in
New Jersey (USA), and with personnel in an USA penitentiary – that allowed
novel ideas to be raised, explored, and tested (page 32).
• Many of the leading researchers could best be described as ‘amateurs’ (pages
35, 38). They were physicians in Liverpool who cared for their patients
during the day and then dealt with medical research projects – usually in the
evening – after their clinical duties had concluded. At the beginning of their
involvement in this research area, they had neither laboratory experience nor
familiarity with many of the basic concepts. Nonetheless, they succeeded in
putting forth and subjecting to experimental test the two-part ‘Liverpool
hypothesis’: that transfer of Rh-positive cells into Rh-negative mothers
typically occurred at birth, not throughout pregnancy, and that the rapid
removal of those fetal cells from maternal blood with anti-Rh (anti-D)
antibody could prevent sensitization.
• The research surrounding treatment and prevention was accomplished with
modest funding (page 45). In the present-day environment of big science and
big budgets, it seems surprising how limited was the funding for this
research. When substantial amounts of external support did come, in the
form of a major Nuffield Foundation grant to the Liverpool group, it was
only after the major part of the testing of the Liverpool hypothesis had
already been accomplished. This Nuffield support allowed the establishment
of a medical genetics research facility at the University of Liverpool which
went on to grow in size and make key contributions in several different areas
of medical genetics in the years that followed. Sadly, the departure of some
of the original researchers left that unit vulnerable and, despite its illustrious
history, it no longer exists.
• The clinicians and researchers were fortunate in the timely arrival of new
technologies – such as flexible catheters which greatly simplified the process of
blood transfusions, the Kleihauer technique which was a crucial tool for
measuring the presence of fetal cells in maternal blood, and the quantitative
measure of anti-D antibody which permitted standardized anti-D delivery –
and rapidly pressed them into service (pages 15, 18–19, 30–31, 43).
xxi
We are deeply grateful to all the participants in this Witness Seminar for their
generosity in sharing their experiences. Decades later, we are still able to draw
inspiration and guidance from these dedicated individuals.
Doris T Zallen
Virginia Polytechnic Institute and State University, Blacksburg, Virginia (USA)
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Professor Sir David Weatherall: We are going to go through the history of the
development of the rhesus factor story and before we start I would like to ask
Doris Zallen to begin with a historical introduction.
Professor Doris Zallen: I have been asked to give some historical context and
raise some questions, and I will try to do all of that. When it comes to sorting
out the history of a medical advance, it is always hard to know where to begin.
But certainly a major historical landmark anchoring today’s discussion would
have to be the work of Karl Landsteiner in 1900, for which he won the Nobel
Prize in 1930.1 Landsteiner discovered the existence of the ABO blood groups,
the cell surface substances produced by genes that endow individuals with their
individual blood types: A, B, O and AB.2 Landsteiner’s scientific finding was
pressed into service. Clinically, of course, it resulted in safer blood transfusions
in humans. Scientifically, it fuelled research efforts to find other such blood
group systems. Initially, very few studies of the blood group factors took place in
Britain. It wasn’t until the 1930s – when J B S Haldane began to use blood types
as human traits in his population genetic studies and when R A Fisher took over
the Galton Chair at UCL and set up a laboratory that focused on blood group
research – that blood groups became an area of active research in the UK.3
One prominent outcome of research in the USA, and a crucial historical
landmark for us today, was the discovery of the Rh factor. Credit for this
discovery still remains the subject of debate. It formed the basis of a lifelong
feud between the two protagonists, Philip Levine and Alexander Wiener. Both
claimed to have found the Rh factor in 1937, although their actual
publications came several years later.4 Wiener said that he and Landsteiner
discovered the Rh factor in humans while they were looking for antisera to as
yet undetected blood group factors, and they were doing this by injecting
rhesus monkey blood into rabbits and guinea-pigs. They named the new
antigen, thus revealed, as the rhesus, or Rh antigen. When the antiserum to Rh
was tested against human blood, they found that 85 per cent of their samples
were Rh positive, 15 per cent were Rh negative. They delayed publication, they
claimed, to improve the process of production of the anti-rhesus serum. Their
The Rhesus Factor and Disease Prevention
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1 Landsteiner (1900, 1901). See also Owen (2000).
2 Landsteiner (1903); Rous (1947). See also Diamond (1980b).
3 Bodmer (1992).
4 Levine and Stetson (1939); Landsteiner and Wiener (1940); See also Wiener (1954, 1969); 
Levine (1984).
work was not published until 1940, three years after their initial studies, when
it became clear that it could explain unexpected haemolytic reactions that arose
during blood transfusions between otherwise ABO-identical individuals. 
For his part, Levine thought he had priority. In 1937 he had found a previously
unknown antiserum in a woman who had given birth to a stillborn infant. This
antiserum reacted with the father’s red blood cells, but not the mother’s. The
same antiserum also reacted with 80 per cent of other blood samples with
which it was tested. Levine’s publication on this case, co-authored with Rufus
Stetson, didn’t appear until 1939, two years later.5 Why the delay? It’s not clear,
but there may have been serious disputes about authorship that arose within
the group itself. What isn’t disputed is that Wiener gave the new factor its
name, Rh, and that Levine explained its role in the disease affecting the family
whose blood he had studied in 1937. 
The particular disease, erythroblastosis fetalis, was one that afflicted many
newborns, about one in 200, and appeared again and again in the same
families. Haemolytic diseases of the newborn had been known and reported in
the medical literature. The first such report describing one of its features,
hydrops fetalis, appeared in 400 BC,6 but little was known of the cause. Levine
had the answer. Rh antibody was formed in an Rh-negative woman when she
was exposed to blood from her fetus, blood that contained the Rh factor. In
this circumstance, the Rh antibody produced by the mother could cross the
placenta and attack Rh-positive fetal cells, often with tragic results. What was
this Rh factor? What were its properties? How was it inherited? Was there any
way to treat the disease? Was there any way to prevent it? Different groups on
both sides of the Atlantic focused their attention on these issues.
Today’s Witness Seminar will bring us to the heart of the Rh factor story.
Among the things we will be trying to discover are not only what happened
and when – not only the timeline – but why it happened and how. How did
Rh factor research take hold in a country where blood group research had been
neglected for such a long time? How was it possible for a group of physicians
at Liverpool to play such a significant role? This is a group that Cyril Clarke
called ‘amateurs’.7 They were physicians who spent most of their time dealing
with clinical duties. They weren’t paediatricians, or obstetricians; they had
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never treated a case of erythroblastosis fetalis; they had no training in serology
or genetics. So how did this unlikely group manage to tame a terrible disease
and bring this episode in medical history to such a satisfying conclusion? There
are many dimensions to the Rh story and it would be wonderful today to have
some light shed on at least some of them. So, Professor Weatherall, we are in
your hands.
Weatherall: Thank you for setting the scene so nicely for us. At the beginning
we ought to at least try to get some general background about the evolution of
interest in blood group genetics and serology in the UK. I think there would be
nobody better to help us than Professor Pat Mollison. Pat, can you lead us off? 
Professor Pat Mollison: Yes. It has already been pointed out that one of the first
labs in this country working on blood groups was the Galton Laboratory Serum
Unit set up by R A Fisher with Rockefeller money in 1935.8 In 1937, by a lucky
chance, Rob Race, a young pathologist destined to become a great figure in
blood grouping, was appointed to help G L Taylor. They worked for the first
few years only on ABO and MN,9 which were (apart from P) the only blood
group systems known at the time, although from the early 1940s they started
on Rh – and I will say a word about that in a moment. Meanwhile, in 1940,
there were four London transfusion centres,10 and the one I worked at, which
was at Sutton, was extremely interested in blood groups. People working there
did some very useful work on dangerous universal donors.11 We had a very
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bright physician, John Loutit from Australia who, with others, carried out very
interesting experimental work in human subjects. It would be quite impossible
to do that now, of course; very little was done in the way of getting permission.
Early in 1942 the US work on Rh became known in the UK. At that time we
had a Canadian physiologist, Omond Solandt, who, unlike me, read journals.
He told me that he had seen an article by Levine and that I should take an
interest in it.12 Meanwhile we were sent some guinea pig anti-Rh from
Landsteiner’s lab. It was a terribly bad reagent and was extremely difficult to
work with. The obvious solution was to find a woman who had had a baby
with haemolytic disease. I went over to the Mayday Hospital in Croydon in
March 1942, and found a woman whose serum agglutinated eight out of the
ten samples tested with it. I gather that Rob Race did much the same in
Cambridge, at about the same time. From then on, we were able to do Rh
grouping. It was possible to diagnose haemolytic reactions due to Rh
incompatibility and to diagnose Rh haemolytic disease, because one could find
the antibody in the mother. A lot of other laboratories during the early stages
of the war were interested in transfusion. For example, the first example of
anti-c was found by McCall in Stoke on Trent, Cappell in Glasgow found anti-
C, and Boorman and Dodd in Sutton found anti-E.13 Race by this time had
taken over from G L Taylor as Head of the Galton lab, and everybody sent
their samples to him. Fisher was still in London at that time as Professor of
Genetics at UCH but he became Professor in Cambridge in about 1943. He
used to go down and see Race regularly and look at his results. There was a
famous day in the pub called the Bun Shop when Race showed him his latest
results. Fisher came up the next morning with his ‘CDE’ idea: the idea that Rh
antigens are determined by three closely linked pairs of allelic genes.14 In the
USA the same Rh specificities were encountered, but it was postulated that
they were determined by multiple alleles at a single locus. One great advantage
of the ‘CDE’ concept was that everybody could talk about it so easily. 
Until 1945 the only method of detecting blood group antibodies was by
agglutination in saline, which detected IgM antibodies. As all immune blood
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group antibodies are, at least partly, IgG, they couldn’t be picked up unless they
happened to have an IgM component.15 It wasn’t until 1944 that Race
demonstrated what he called an ‘incomplete antibody’:16 incomplete Rh
antibody would attach to cells, and stop them from being agglutinated by other
anti-Rh antibodies. Almost immediately afterwards there was a flood of tests that
would detect IgG antibodies. Most famously, Coombs, working with Race and
Mourant in Cambridge, developed the antiglobulin test.17 Diamond and Denton
in Boston discovered the agglutination-enhancing properties of albumin as a
medium, and Pickles in Oxford showed that enzyme-treated red blood cells were
agglutinated by IgG antibodies.18 These discoveries opened up the field
tremendously. From about 1945 onwards, one could detect so many new
antibodies and one blood group system after another was discovered. 
The only other thing I wanted to comment on is that once blood group
antibodies could be identified so easily, many strands of interest developed.
There was the biochemical approach, particularly by Morgan and Watkins on
the ABO and Lewis systems;19 there were the genetic linkages between blood
group systems, the first one perhaps was between MN and Ss, picked up by
Race and Sanger.20 Then there was the association between blood groups and
disease. I think the first there was possibly Ian Aird, the surgeon, who
identified the strong association between blood group O and peptic ulcer.21
Then there was the difference of frequencies of blood groups in different races,
for example the increased frequency of D-negatives in the Basques.22 From the
clinical point of view, there were incompatible reactions and the whole
question of haemolytic disease in the newborn to be investigated. 
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Weatherall: Thanks very much for starting us off so well. Dr Beryl Corner,
would you like to fill in on some of that?
Dr Beryl Corner: The Army Blood Transfusion Service was set up in 1939, at
the onset of the war, by sheer chance in the grounds of Southmead Hospital in
Bristol.23 Southmead Hospital then opened a very large maternity department
with 140 beds altogether, and the Medical Officer of Health for Bristol
(Professor R H Parry), a very progressive man, had arranged antenatal clinics
all over the city, and means of antenatal blood testing for women in the city.
Colonel Lionel Whitby was in charge of the blood transfusion service and
from the beginning he offered his services to any clinicians in the area who
wished to use them. So as soon as the rhesus factor had been discovered, as we
have already heard, by Wiener and Levine,24 Lionel Whitby began to include
this test on the blood that he examined from donors. So he had the rhesus
typing established. By 1943, all bloods coming from antenatal patients in the
area had rhesus typing performed on them by Whitby and his group. Geoffrey
Tovey was the lieutenant there who was responsible for all this. In 1943 our
first case of Rh haemolytic disease was diagnosed and treated by Geoffrey
Tovey and myself: a three-hour-old baby, born in a local maternity hospital,
and a very, very sick baby, pale, with bruising and petechiae all over. Geoffrey
Tovey established that this was in fact a case of Rh incompatibility. The baby
was far too sick to contemplate cutting down on the veins, which would have
been necessary in those days, with the primitive equipment available, and so I
actually treated the baby directly into the bone marrow. I gave about 50 ml of
Rh-negative blood into various places of bone marrow and saved the baby’s
life. That patient survived and was followed up by us, and when he was aged
18 he became a blood donor, rhesus positive.
The other thing I would like to say is that I spent a day at Aldershot in 1990,
at the blood transfusion service there, and I went through the archives of all
the correspondence and all the papers that had been collected by Lionel
Whitby and Geoffrey Tovey and the correspondence with the War Office. I got
some statistics about blood transfusions that had been done by the Army
Blood Transfusion Service during the war. One of the interesting things was
that they established an Rh-negative panel of donors, with 79 donors, up to
1945 and they also established donors for the other blood groups as well, but
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they had actually a Rh-negative panel of 79 donors at that stage. At that time,
of course, we knew nothing about exchange transfusion, but we were regularly
treating babies who were diagnosed as having haemolytic disease, and we were
treating them just with straight blood transfusions. We reckoned that we cut
the mortality by 50 per cent for haemolytic disease due to Rh incompatibility.25
Weatherall: Thank you very much indeed. Just a matter of technology: was
intramedullary transfusion, that is transfusion straight into the bone marrow,
a standard practice for neonates at that time?
Corner: No, it wasn’t. The problem was that there were no suitable needles
small enough to put into veins of babies, and any transfusion attempted in
1943 on a baby meant a cut-down needle, and inserting an adult-sized
cannula, and that particular baby was in no state for that procedure.
Weatherall: What we have heard from Pat [Mollison] is a bird’s-eye view of the
development of knowledge about the genetics, the early diagnostic testing, the
importance of the Coombs test and so on, and the kind of first stuttering
approaches to treatment. Is there anybody else who would like to say anything
about that particular period – that is, the further development of knowledge
about the genetics of the system – and what you were thinking at that time, or
the idea of preventing this disease, given that you knew about the basic
pathophysiology very clearly at that time? Were there any thoughts about
prevention for the future?
Mollison: I think the idea of artificial insemination from Rh-negative men was
certainly discussed.26 It was quite a lively topic at one time. 
Weatherall: That was your idea was it?
Mollison: No, no.
Dr Derrick Tovey: I was going to carry on from Dr Beryl Corner because I
went to Bristol to work with Geoffrey Tovey, and it is important to realize that
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we were doing exchange transfusions every day. There were, in fact, two or
three mothers every day in England and Wales who lost a baby with Rh. An
important factor in Great Britain was that most transfusion centres then tested
all Rh-negative women for antibodies, and this allowed for many obstetric and
paediatric centres, such as Bristol, Newcastle and Lewisham, to specialize in
the management of these mothers and their babies.27 I have one anecdote to
add. While I was there, I had a phone call from a maternity unit in Gloucester
asking if I wished to do a post mortem (pm) on a rhesus baby. I said I wasn’t
particularly interested in doing a pm, but when did it die? ‘Oh’, she said, ‘It’s
not dead yet’. So I put the equipment in the back of the car, collected our
nurse, and we drove up to Gloucester and did an exchange transfusion. I am
only pointing this out because of the importance of having regional centres
that were expert in this condition.
Corner: I should have added something to what I said just now. By 1945,
every baby born under our service had its cord blood done, with all the
grouping factors, and if the mother was Rh-negative, the Coombs test was
done. By 1945, we were doing Coombs testing on all babies of Rh-negative
mothers on blood from the umbilical cord. 
Dr Timos Valaes: I want to go on with the story that Dr Corner, my mentor
at the time, started. I joined the paediatric staff at Southmead Hospital in
1956. The excitement of treating erythroblastotic babies with exchange
transfusion almost every day became the turning point in my professional life
and led me to neonatology.28 If I am allowed to continue a little on the subject,
I consider the emergence of neonatology and, a little later, of fetal medicine as
collateral benefits of the work done by people like Professors Mollison and
Coombs, who provided the definitive tests for recognizing maternal
isoimmunization and its consequence: haemolytic disease of the newborn
(HDN). Things moved very fast. By the time the techniques for in utero
interventions were fully developed, the advances in Rh disease prevention
resulted in diminishing numbers of affected fetuses. By the 1970s a rhesus-
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negative young woman could be reassured that the probability of survival for
her progeny was as good as that of a rhesus-positive woman.29 This was an
enormously brighter outlook for the lives of millions of prospective mothers
and – I must add – fathers.
Weatherall: Thanks very much. What we have done, in a sense, apart from
outlining the genetics, was to jump from the very first efforts of a kind of
treatment to the time when exchange transfusion, intrauterine transfusions
became more routine, and I wondered if it would be possible perhaps for Charles
Rodeck to introduce this area and try to put it in a kind of temporal perspective
for us at the moment, because we seem to have jumped straight from the very
first primitive (if you might excuse the term) effort trying to get some blood into
a baby to the time of well-developed technology of exchange transfusions.
Professor Charles Rodeck: Thank you. There are other people in this room
who were in the field earlier than I was, and who, I hope, are going to
contribute. But I think that as far as attempting to treat the problem while the
patient is in utero, one of the first crucial steps was to refine diagnosis and
prognosis, and to define who needed treatment and who did not. That meant
making use of the knowledge that these babies became jaundiced and that the
bilirubin levels were high in the amniotic fluid. Now, when this was being
thought about, and the initial efforts were being done, an invasive procedure
on the uterus was very, very rare indeed, and thought to be partly an invasion
of a sacrosanct area, and partly also very risky. I think the name most associated
with those early studies on bilirubin levels in the amniotic fluid is Douglas
Bevis, who was working in Manchester in the early 1950s.30 Then in the late
1950s and early 1960s there was William Liley in New Zealand who took it
further and developed the charts for the assessment of prognosis.31 He did
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spectrophotometric measurements on the amniotic fluid to measure bilirubin
and found that these were correlated with outcome. Many centres, of course,
were working in this area by then and were starting to develop their own
charts, and so the Liley charts, although they were probably the best known,
were by no means the only ones. Again, some of the other people here might
wish to comment on that.
With a method available to determine the severity of the condition, which was,
I would say, reasonably accurate from late second trimester onwards into early
third trimester, the next question was what to do. Early delivery so that the
baby could have the benefit of exchange transfusions postnatally was the
standard treatment and it had a great impact, but it still didn’t help those that
were too preterm to deliver and not yet viable. In those days, of course,
neonatal units weren’t prepared to accept infants born at 24, 25 or 26 weeks.
The only option they had was to die in utero. 
It was Liley again who then introduced the next major development. He did
the first fetal intraperitoneal transfusion in Auckland, New Zealand, in 1963.32
Very rapidly, many other centres around the world took this up. It was a highly
courageous and risky intervention, because ultrasound guidance wasn’t
available then.33 There was only one’s sixth sense and a friendly radiologist who
might want to get involved and take X-rays after injection of contrast media
into the amniotic cavity. It had quite a high mortality rate, partly because it was
reserved only for the sickest babies. Despite that, it spread around the world. I
believe the first transfusion in this country was done by Mrs Jadwiga Karnicki
at Lewisham. As soon as she heard of Liley’s success, she whizzed off to New
Zealand, and it was a case of ‘see one, do one, teach one’, I think. That was
then the era of intrauterine treatment with intraperitoneal transfusion for
almost 20 years. 
Weatherall: Okay, so phase one, we are talking about intrauterine transfusion.
Are there other people who have reminiscences or memories of what sounds
like a fairly hairy period of development?
Corner: I think we have jumped a bit, if I may say so, because exchange
transfusion was the big breakthrough, and this was first described by the
Boston group in the USA in 1946. Our first three exchanges were done by
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Geoffrey Tovey and myself in 1948. Then exchange transfusion became
routine treatment for babies diagnosed with haemolytic disease and other
jaundiced babies as well during the 1950s (see Figure 1).34 It was not until the
1960s that the intrauterine transfusion was well developed,35 when it was
realized that, although exchange transfusion was saving a great many babies
who were born at birth with obvious early signs of haemolytic disease,
hydropic babies could not as a rule be saved by that means. Therefore the
endeavour was made to find means of getting to the hydropic babies before
they became hydropic. In other words, this led to the desire for fetal
transfusion and in the early 1960s this started.
Zallen: What was the success rate of the exchange transfusions? Do you have
an estimate of how many babies survived and how many were lost?
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Figure 1: John Walker-Smith as an obstetric senior house officer in 1961, performs 
an exchange transfusion on a newborn with haemolytic disease due to rhesus incompatibility
at the King George V Memorial Hospital, Sydney. Walker-Smith (2003).
Corner: Yes. When the exchange transfusion techniques really became
established, which was during the 1950s, the survival rate was very high
indeed. By 1955 we had exchanged well over 100, with 146 term infants, or
near-term, and 16 premature babies as well. So it was a very high survival rate
at that time when we got the technique really established. Our biggest problem
then, in the 1950s, was the lack of laboratory facilities, especially
micromethods that could give rapid results on small quantitites of blood for
estimating bilirubin in the newborn infant, because the decision as to when to
exchange depended on an estimation of the rate of rise of bilirubin to the point
where it could cause kernicterus – kernicterus then became the subject that
was being researched during the 1950s. I myself wrote a paper on kernicterus
and prematurity, which was published in the Lancet in 1950,36 in which we
examined the deaths from hyperbilirubinaemia of premature babies. This was
also the principal cause of death of the babies with haemolytic disease due to
rhesus or other blood group incompatibility, for example ABO; that also came
to light at this phase in the 1950s. When we discovered kernicterus we realized
that this had got to be prevented by blood exchange, before the bilirubin in the
blood rose too high, but our biggest problem was the lack of laboratory
facilities for estimating serum bilirubin quickly. Bilirubin in severe cases had to
be estimated two or three times in 24 hours, and we needed instant results, not
results the next day, which was what most laboratories were capable of doing
at that time. So in the 1950s this was an enormous stumbling block to the
progress for treatment of this disease.37
Dr Archie Norman: I came into the rhesus field later than Beryl, and I have
much less experience than she has. Mine was very much that of the plumber, with
some advisory role as well. But, in order to come here today, I dug out my 1954
edition of Recent Advances in Paediatrics, and read Mollison’s chapter there, which
is, I think, excellent, and covers the whole field.38 His conclusions there were all
rather tentative. I then picked up the 1958 edition and read Lathe and Claireaux’s
chapter39 in which almost all of what Mollison had suggested had been confirmed,
and by then the use of estimations of bilirubin for controlling
hyperbilirubinaemia and preventing kernicterus were almost, or were, routine. In
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addition, exchange transfusion had become accepted. At that time I did most of
the exchanges at Queen Charlotte’s Hospital, London, and, I must say, an
exchange transfusion even then was a matter of some anxiety. In about 1951 Lathe
had said in his paper that it was a matter of great concern.40 To get a rather firm
plastic catheter into the umbilical vein of a small, perhaps anaemic and rather ill,
baby was not always easy, and the estimations of the amount of blood you gave
them also needed care. Towards the middle or latter end of the 1950s, soft vinyl
catheters came into use and that made life very much easier, together with the
two-way tap. So exchange transfusions became, I think, considerably safer and
much easier to perform.41 At the Royal Society of Medicine, I managed to find the
Queen Charlotte’s Hospital reports from 1950 to 1960 and found that there was
a steady fall in mortality, a steady fall in kernicterus, but no change in neonatal
deaths. Now that was probably because we were using early induction of labour
more, so that there was a shift from the stillbirth rate to the neonatal. 
I found that dealing with rhesus problems was emotional and stressful. Not
only was there the problem of what one was going to do, but also of
collaboration with the obstetricians.42 When I first went there, we were not on
the easiest of terms with the obstetricians, who saw little use for paediatricians.
Fortunately, once we had begun to do the exchange transfusions, they felt they
had got rid of something they weren’t too keen on. Furthermore, we had a very
friendly collaboration in the question of when and if to do an early induction. 
I have little else to say, except that one can forget so easily, I think; I don’t know
how many of the practising doctors present have ever seen a case of kernicterus,
but it’s a dreadful condition. And for the woman who had already lost one
baby, or who had a severely affected baby, to go through pregnancy and labour
again is extremely stressful and one became very closely associated with them
during that time. As a result, when one was able to produce a healthy baby,
after exchange or otherwise, I found that the gratitude from parents was very
much more marked than for almost any other condition I had dealt with.
From my own point of view, maybe irrelevant but a thing that I have never
forgotten, was driving home in the early morning after an emergency
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exchange, and that feeling of elation that one really has done something for
once. It was great. 
Mr Elliot Philipp: Dr Karnicki has been mentioned. She published three
separate papers on intrauterine transfusion,43 but she did it under the stimulus
of a man who has not been mentioned today and that is Alistair Gunn,
obstetrician at Lewisham Hospital, who was her senior colleague. Now the
difficulty with preterm delivery was inducing labour so that the risks of
prematurity and the baby dying from prematurity would not be as great as
those of dying from the rhesus disease, kernicterus and so on. Alistair Gunn
became quite an expert at assessing weight just by palpation. He was quite
remarkable at it, and it was he who persuaded Dr Karnicki to do intrauterine
transfusions. They, I think, were the first non-teaching unit (at Lewisham) to
do exchange transfusions,44 and they taught me to do them. I did a very large
number of them too, and I agree absolutely with Dr Norman, that it is a very
hazardous and nerve-wracking procedure; and you drove home after doing
them with a great sense of satisfaction.
Dr Jean Smellie: I don’t have anything like Dr Corner’s or Dr Norman’s
experience, but I was able to observe the change in attitude to exchange
transfusion after its early introduction and also the effect of the many man-
hours spent by paediatricians on exchange transfusions, often needing repeats.
The first ‘exchange’ I saw was on Christmas Day 1949 when I was an
undergraduate on the ‘list’. It was well remembered because after it I walked from
UCH to Waterloo, to attend (rather late) a family lunch where a sceptical medical
uncle said, ‘Well, it won’t do any good anyway, will it?’. This was very much the
general attitude to erythroblastosis and exchange transfusion at that time.45
However, the figures for St Mary’s Hospital, Manchester, for the three years
from 1949 up to 1952 (when exchange transfusion was well-established)
showed a dramatic reduction in kernicterus and fetal loss, among 90–100
mothers with rhesus incompatibility per annum. The UCH figures for much
smaller numbers for the decade from 1949 to 1959 – involving 116 mothers,
the majority with a previously affected fetus/infant – showed a similar effect.
Two of the seven neonatal deaths that occurred were during exchange
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44 Berriman (1971).
45 Diamond (1947, 1948).
transfusion; there were 12 stillbirths and none of the 97 survivors had
kernicterus. Not surprisingly, when the gestation of these pregnancies at the
time of delivery was related to outcome, the risk of hydrops increased with
length of gestation and the risk of neonatal respiratory problems increased
with early induction of labour. So these were major reasons for seeking some
means of preventing the condition. 
Professor James Scott: A small point related to kernicterus, which we referred
to, and Grant Lathe’s work at Queen Charlotte’s. I came across Lathe at
Charlotte’s in 1951, 1952, and I met up with him again in Leeds in 1961. At
a funeral more recently – which is where most of my encounters are! – I re-
introduced myself to him and he said, ‘Good God, I thought you were dead!’
As far as I know he is still alive, at least he was two months ago, and a resident
in Leeds. I think it would perhaps be a pity if he weren’t contacted to make a
contribution to whatever comes out of this, because he was right at the centre
of the work on kernicterus.46
Mr Humphry Ward: I am simply going to add to what Charles [Rodeck] has
said, although I think we have perhaps jumped a little bit ahead, because I
think one of the key obstetric landmarks was the use of amniocentesis. I think
it was Walker who suggested that it was pointless planning amniocentesis
much before 34 weeks, because there was nothing that paediatricians could do
to save these babies. It is fascinating to look back at Liley’s original data and
read his closing paragraph, because it sums the whole thing up. He says, ‘The
aim of the exercise, that is of intrauterine transfusion, is simply to arrest
deterioration if possible and gain a few extra weeks of gestation, so that the
skilled paediatric care of severe haemolytic disease is not nullified by gross
prematurity’.47 That was the key thing, of course, about Liley’s work. I should
say that I had the privilege to work with him in the middle 1960s and he was
the most remarkable man. He was a person who knew everything; there was
no topic that he didn’t have an opinion on. He was a very humble man
actually, and he never wanted to boast about what he considered was such a
simple principle of physiology that he was putting into practice. At the time
he was a senior research fellow, but he then became a Professor of Physiology,
neonatal physiology, I think, actually. He was a wonderful man.
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Professor Charles Whitfield: You mentioned, Mr Chairman, that the early
uterine transfusions were hairy procedures. The same things applied to
exchange transfusion. The first exchange transfusion was in 1946 by
Wallerstein in New York.48 He used the sagittal sinus to put in the blood and
he drained it from a peripheral vein. Even before that, 20 odd years before, in
Toronto, a man called Hart had done a similar case: a lady had a succession of
stillbirths, and I have seen the notes of gross oedema and although it wasn’t
then recognized as a case of rhesus, it clearly was. My first contact with
exchange transfusion, since we are reminiscing, was in 1949 as a student in
Belfast, when I was hauled in to assist with an exchange transfusion and my
job was to keep a count of the blood taken out (this was measured), and also
to wipe the clots with a wipe or cotton wool (I can’t remember), so that the
outflowing blood could be measured in a galley pot; the transfused blood was
given through a vein exposed by a small incision at an ankle (in the then usual
way). That baby lived. Then in 1954 I got to Malta and within a few days was
doing an exchange transfusion with glass cannulas and bits of metal linked
together with rubber tubing, and with just a two-way syringe. The Henderson
syringe with three-way flow (in, out, and for the blood) made a huge difference
in this experience we have mentioned. Later on, the better plastic catheters also
made such a huge difference, and the procedure ceased to be a nightmare.
Weatherall: What you have been describing is an extraordinary learning curve,
from the mid-1940s through the following ten years, which relied not only on
technical skills, but also on interaction with the laboratory, on the
development of better methods for measuring bilirubin (also, presumably, the
identification of critical bilirubin levels at which babies were at risk of
kernicterus), and also on the ability of the laboratory to produce appropriate
blood for exchange. Where were these fundamental, important bits of clinical
research done? Were a number of them done in this country?
Mollison: We did produce evidence that kernicterus didn’t occur with serum
bilirubin levels of 18 mg per decilitre or less,49 and this figure proved to be a
useful guide.
Weatherall: What about these other technical developments, particularly the
actual equipment and technique, the ability to deliver these transfusions? You
are saying that there were better needles, very simple things like that. How did
these developments come about?
Corner: There was enormous pressure from the few paediatricians who existed
in the 1950s and who had found their way even into maternity departments.
We literally moaned and groaned to our biochemists that something must be
done. But it was very difficult to get something done because in the 1950s, in
the post-war phase of development of laboratories throughout the country,
biochemists were very concerned with mass production of results of tests for
electrolytes for instance, and to have to produce an urgent bilirubin result on
a baby, where 5 ml of blood was what we were asked for very often, was
something that was a bit tiresome, to tell the truth. I have rather sad memories
of senior registrars standing at the telephone most of the day in the 1950s
trying to get a bilirubin result back from a teaching hospital laboratory because
they just had not been able to put it through with the techniques that they had
at that time for doing it. I always say that the biggest advances in paediatrics
came from plastics and electronics: plastic tubing for everything, including
drip feeds and IV treatment, and then electronics in the equipment for getting
quick results.
Coombs: Could I just point out that Wiener’s technique of using an albumin
solution to demonstrate haemagglutination did give positive results mostly –
but Wiener was wrong in calling this agglutination ‘conglutination’? That term
had been given to a phenomenon first described in 1906 by Bordet and Gay,
and whose mechanism was clarified by Bordet and Streng in 1909.50 It involved
a heat stable component of bovine serum named conglutinin, which caused the
clumping of sensitized red blood cells, usually sheep or ox cells, in the presence
of a non-haemolytic complement. In diagnostic laboratory tests, a
conglutinating complement absorption test has similar uses to a haemolytic
complement fixation test. 
Dr Sheila Duncan: I think it’s quite important to put the 1950s and 1960s
into some sort of context from the obstetricians’ point of view. Exchange
transfusion was certainly an option after 34 weeks. Yet, even when it became
more secure and successful, there was still a big problem for the obstetrician
because so many of the more severely affected babies didn’t make it to 34
weeks, as we have said. The perinatal meetings at that time were absolutely
dominated by rhesus immunization. There were also preterm babies and babies
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with congenital abnormalities, but it was the rhesus cases we thought that we
could perhaps do something about. The severe intrauterine cases of rhesus
disease were extremely important and sometimes dramatic, because if a woman
had a severely affected baby who died in utero well before 34 weeks, she often
retained that baby in utero for some weeks. Usually she had had previously
affected babies and this was the end of the line. Indeed her safety was at risk
because there wasn’t much idea of inducing labour at 30 weeks with a dead
baby at that time. When she did labour, she was subject to DIC (disseminated
intravascular coagulation), or afibrinogenaemia as we called it then, and her
life was in some danger. So, the prospect of intrauterine transfusion was really
The Rhesus Factor and Disease Prevention
20
Figure 2: Radiograph taken on day after
amniocentesis for bilirubin assessment and
followed by contrast (1975). Swallowed
contrast outlines the fetal gut, as well as
remnants still in amniotic fluid.The
delineation helped the insertion of the
Touhy needle into the fetal abdomen.The
fetus was in the breech position.
Figure 3:Touhy needle inserted into the fetal
abdomen (1975). Some obstetricians fed a
catheter into the fetal abdomen and gave
the blood slowly. Others (as here) relied on
the needle and gave the blood over about
20 minutes.
very important. The success rate was low at the beginning and, when it began
to be used more widely in the mid-1960s, the failure rate was still really quite
high. But in the severe cases, diagnosed by amniocentesis and using Liley
curves, there was more to gain than to lose. The technique gradually
developed, and this I think should be commented on. Amniocentesis was
done, and some contrast was injected, which the fetus swallowed, so that
within 24 or 48 hours when you had the amniocentesis result and the blood
was available and you were ready to do it, the baby had outlined its gut. 
The techniques by today’s standards were extremely crude. X-ray screening
helped to locate the needle in the peritoneal cavity (see Figures 2 and 3). A
little contrast medium could be injected to identify this positively. I have seen
many pictures of IVPs, cystograms, and the contrast in various cavities, but
nevertheless even with the 30 or so per cent success rate, which I think is what
it was in the early days, gradually increasing, they were very rewarding
situations. But there was still a high fetal loss rate. It also sometimes stimulated
labour and although that was unfortunate, the alternative was sometimes
worse and I think this area of activity should be recorded. 
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Figure 4: Curves relating the haemoglobin concentration of cord blood to the chance of
survival, with different forms of treatment. Ex, exchange transfusion (sometimes less than 50
ml blood/lb body weight); No Ex, simple transfusion or no transfusion; Mat, mature, that is
born at term or within ten days of term; Imm, immature, that is, born 35–18 days before term.
Redrawn from Armitage and Mollison (1953). See note 51.
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Valaes: I want to remind the audience that the only multicentre randomized
trial on the treatment of Rh hemolytic disease of the newborn was done in
England.51 It convincingly demonstrated the superiority of immediate
exchange transfusion over simple transfusion so that the issue was settled once
and for all. Early exchange transfusion was considered important not only for
theoretical reasons but for a practical issue as well. With the stiff nylon tubing
used to catheterize the umbilical vein, the success rate for later attempts was
low (this has already been mentioned by Dr Norman).52 The criteria for
deciding that treatment was needed were based on the level of cord blood
haemoglobin. In terms of the multicentre clinical trial, this study was again a
first for establishing the need for careful standardization of critical laboratory
measurements – in this case haemoglobin. When, appropriately, the emphasis
shifted to bilirubin measurement and, if necessary, repeat exchange
transfusions, the lack of satisfactory standardization of bilirubin measurement
plagued the management of neonatal jaundice. This is a problem not totally
resolved even now. I hope that Professor Mollison will forgive me for taking
the words out of his mouth. 
Tovey: Just to put into perspective all these new techniques; in 1950 the deaths
per 1000 births in Britain was 1.6; by 1970 when you had exchange
transfusion, amniocentesis, premature deliveries, intravenous therapy, it had
dropped only to 1.2 deaths per 1000 births. Five years later, it went down to
0.4. Of course, what happened in 1970, we all know; we will hear later. But it
is interesting that the total deaths per 1000 births didn’t drop terribly much in
that period of time 1950–70 (see Figure 5).53
The Rhesus Factor and Disease Prevention
22
51 Mollison and Walker (1952); Armitage and Mollison (1953), see also Figure 4. Professor Patrick
Mollison wrote: ‘The figure summarizes some of the results of the controlled trials of treatment referred
to by Dr Valaes. In infants not treated by exchange transfusion, the chance of survival was inversely
related to the cord blood haemoglobin concentration. At all degrees of anaemia in mature infants,
survival rates were greatly increased by exchange transfusion.’ Note on draft transcript, 4 August 2004.
52 See page 15.
53 Tovey (1984): 100. See also Clarke and Mollison (1989). Dr Sheila Duncan wrote: ‘A considerable
proportion of the fetal losses due to rhesus immunization were stillbirths or deaths before 28 weeks which
would not be included in the figures. Even after 1970, it was many years before already immunized
women had finished child-bearing.’ Note on draft transcript, 27 September 2004. Professor Derrick
Tovey wrote: ‘Although the measure prior to 1970 when anti-D prevention was introduced did result in
a slow decline in infant deaths due to Rh it was only after the introduction of Rh prophylaxis that a
dramatic fall in infant deaths occurred.’ Letter to Dr Daphne Christie 1 October 2004.
Weatherall: I think that’s an excellent point to start moving on. Pat Mollison
set the scene in a sense, in starting to ask the question that Doris Zallen
addressed at the beginning and that was ‘why Liverpool?’. As Pat pointed out,
in the early development of human genetics, particularly medical genetics, the
blood groups were really the only markers, and it was therefore almost
inevitable that anybody who became interested in genetics in the 1950s would
at least be thinking about blood groups. Maybe that’s not the reason, but John
Woodrow is going to try to give us some background about how these things
might have started to develop in Liverpool.
Professor John Woodrow: I speak with some trepidation, because I feel that
the ghost of Cyril Clarke is going suddenly to appear among us, and tell us how
it all really happened. It is reported that J B S Haldane used to say in the 1930s
and 1940s that in the whole world there were only about half a dozen people
who knew much about human genetics, and all but one of those were
Englishmen.54 The work of these pioneers was carried out either in London or
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54 See Kevles (1995): 205. The people include Haldane himself, Fisher, Hogben, Penrose, with the
non-British one being the Swede, Gunner Dahlberg. 
Figure 5: Perinatal deaths due to anti-D haemolytic disease of the newborn per 1000 births.
Adapted from Tovey (1984): 100.
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not many miles from London and it was some time before involvement in
research into human and clinical genetics spread to other parts of the country.
In the case of Liverpool it was not until the mid-1950s55 and this came about
because of a seemingly minor event, that is the appearance in 1952 in the
Amateur Entomologists’ Bulletin of an advertisement from Philip Sheppard of
the Department of Zoology in Oxford, seeking pupae of the swallowtail
butterfly Papilio machaon. Cyril Clarke responded to this and it is worth
reflecting on the fact that this exchange was to have a profound effect, not only
on their lives but also on those of several people who are present today. Cyril
had recently discovered how to hand mate swallowtail butterflies and had
carried out some experimental crosses between two related species. The two
soon met and began their collaborative work on the genetics of Batesian
mimicry. Cyril’s enthusiasm and energy and Philip’s expertise in genetics
together with his scientific rigour, proved to be a powerful combination. As far
as I am aware, Cyril had not previously had any particular interest in human
genetics, but the possibility of working together in this area was discussed and
Philip suggested ‘blood groups’ as a basis for a programme of clinical research.56
Why blood groups? On his return from the war Philip had gone up to Oxford
in 1946 to read honours zoology. There he came under the influence of E B
Ford and subsequently obtained his DPhil on the population genetics of
butterflies and snails. Ford was much concerned with the evolution and
maintenance of balanced polymorphism. He had worked with Ronald Fisher
who over the years made major contributions to several areas of human
genetics. Fisher, as has been already mentioned, set up a blood-grouping
laboratory at the Galton Laboratory in 1935.57 There were three areas in which
the blood group polymorphisms played an important role in the study of
human genetics in the early decades of the century.
Firstly these polymorphisms were the only basis for testing the new ideas on
population genetics as exemplified by the works of Hardy and Weinberg and
this led, for example, to the clarification of the genetics of the ABO locus by
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55 See Zallen (1999): 197–216.
56 A very brief account of the prevention of Rh haemolytic disease is given in a recording of Professor
Philip Sheppard, 18 March 1968, available in the Genetics Society Archive (1968; SID I, 1–180),
John Innes Centre Archives, Norwich.
57 See note 8.
Felix Bernstein in 1924.58 Secondly was the question of genetic linkage. There
was a wish to emulate the achievements of the Drosophila geneticists and
establish genetic markers on as many chromosomes as possible. It was hoped
that the slowly increasing list of blood group polymorphisms might provide a
basis for this and thus enable clinical geneticists to furnish a more exact
prognosis for individuals in families affected by mental deficiency, Huntington’s
chorea etc. There was the possibility of detecting the heterozygous carriers in
conditions such as Friedreich ataxia and phenylketonuria. The first to provide a
satisfactory method for determining linkage was Bernstein in 193159 and he was
followed in this by Hogben, Haldane, Fisher and Penrose. The early attempts
to demonstrate linkage proved disappointing and it was not until several
decades later that real progress became possible.
The third application of blood groups was with regard to the possibility of
population associations between blood groups and clinical disorders. It is
worthy of note that this question was being investigated as early as 1917 at the
Mayo Clinic in Minnesota and some negative results were published in 1921.60
We now return to E B Ford in Oxford, who in 1945 suggested that a search
for population associations between the ABO and secretor polymorphisms and
disease might well be productive.61 Philip Sheppard would have been well
aware of this and so it is not at all surprising that when he began working with
Cyril Clarke the opportunity was taken to initiate such studies. Much work
along these lines was carried out in Liverpool in relation to peptic ulcer,
rheumatic fever etc. but the results did not lead to any major advance in our
understanding of disease causation.62
The work on Batesian mimicry in swallowtail butterflies at first suggested that
the variation of wing pattern which allowed for the mimetic forms to evolve,
was based on a series of alleles at a single locus.63 However, further experiments
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60 See, for example, Buchanan and Higley (1921).
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62 See, for example, Aird et al. (1953, 1954).
63 This was discussed in an interview with Clarke arranged by the Royal College of Physicians and
the School of Biological and Molecular Sciences, Oxford Brookes University, UK. 1986. See Sir Cyril
Clarke in interview with Sir Gordon Wolstenholme, 15 May 1986 (Medical Sciences Video Archive
610.695/CLA). Oxford: Oxford Brookes University. 
strongly favoured the existence of a group of closely linked loci with a
particular group of alleles, which constituted what Darlington and Mather had
referred to as a ‘super-gene’.64 Several years previously the complex serology of
the Rh antibodies had been gradually revealed, and provided a challenge to
those attempting to understand the genetic structure of the Rh system. Pat
Mollison has told us how Fisher put forward the concept of three closely linked
loci and this proved very useful in practice and was widely accepted.65 There was
one person who bitterly and persistently disagreed with this interpretation and
that was Alex Wiener. He insisted on a proprietary right to the Rh system of blood
groups, in particular that the Rh antigenic specificities resulted from the presence
of a series of alleles at a single Rh locus and that his nomenclature should be the
only one used. His somewhat vituperative letters and diatribes directed at Rob
Race were well known in Liverpool, and I think Cyril admired the great
forbearance displayed by Race. Cyril and Philip thought that there was a parallel
between the Fisher–Race model of Rh genetics and that of Batesian mimicry and
this led in turn to an interest in Rh haemolytic disease of the newborn.
A remarkable feature of Batesian mimicry is that it is only expressed in females,
and this implies that the genetic determinants of maleness are suppressing the
expression of the genes involved in mimicry. In other words there is gene
interaction. Philip Levine had reported in 1943 that when he studied a group
of Rh immunized mothers, there was a lower than expected frequency of
instances where the father was ABO incompatible with the mother, for
example father group A and mother group O.66 This finding received support
from the experimental work of Curt Stern who injected ABO-compatible and
incompatible RhD-positive blood into RhD-negative subjects and confirmed
the protective effect of ABO incompatibility.67 Later Nevanlinna showed that
the pregnancy that induced primary Rh immunization was usually the one that
preceded the first affected child and that in the great majority of instances the
child in this pregnancy had been ABO compatible with the mother.68 One can
calculate that of all immunized mothers, approximately only 1 in 35 had been
initiated by an ABO incompatible pregnancy. 
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67 Davidsohn et al. (1956); Stern et al. (1961).
68 Nevanlinna and Vainio (1956).
It was considered that the interaction between the Rh and ABO systems was
‘similar to’ the interaction between the genes determining sex and those
determining mimicry in the swallowtail butterflies.69 I will stop there because
Ronnie Finn is going to tell us what happened next.
Weatherall: That’s really set the background very nicely.
Zallen: If R A Fisher hadn’t hypothesized a cluster of loci or a ‘super-gene’, do
you think that the Rh locus would have attracted any interest in Liverpool? I
just wondered because Wiener, of course, was very insistent that his model of
one locus with many alleles, and his notation, be accepted. If that had been the
case, there might not have been the idea that the Rh locus was something like
the butterfly locus responsible for mimicry.
Woodrow: When Cyril Clarke and Philip Sheppard initiated the studies
concerning the possible association of blood groups and disease, there was no
particular interest in the Rh groups. Cyril, in his paper in Scientific American,
after describing the genetics of mimicry in butterflies, states that ‘we could not
help noticing certain striking parallels between the inheritance of their wing
patterns and inheritance of blood types in man’ and then goes on to refer to
the Fisher/Race model of the Rh system.70 If the latter had not been previously
described, it seems unlikely that Cyril’s attention would have been drawn to
the Rh groups and thus to Rh haemolytic disease of the newborn and to the
protective affect of ABO incompatibility.
There is I think one lesson that the controversy between Fisher/Race and
Wiener teaches, and that is that such controversies are usually not solved by
further polemics but by advances in knowledge, which in turn are often the
result of applying new technologies. Thus one had to wait for advances in
molecular biology before it became possible to make progress in understanding
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69 Professor John Woodrow wrote: ‘The process of Rh immunization depends in the first place on
the relationship between the Rh alleles of mother and fetus, that is the mother must have no RhD
alleles and the fetus must be heterozygous RhD. A secondary determinant of Rh immunization is
the relationship between mother and fetus at the ABO locus such that where the mother is, say, group
O and the fetus is group A, the risk of immunization is much decreased. In neither mother nor fetus
is there any interaction between the Rh and ABO loci. This is in contrast to the situation in Batesian
mimicry where in the individual butterfly there is interaction between the male determining locus
and the cluster of loci determining mimicry. That being said, the view may be taken that in the light
of history, the important thing is that the attention of Cyril Clarke was drawn to the protective effect
of ABO compatibility.’ Letter to Dr Daphne Christie, 27 November 2003.
70 Clarke (1968).
the genetic structure of the Rh system and this is work that is still continuing.71
There are people here today who can update us on that.
Weatherall: But it hadn’t been. I saw Ronnie Finn shaking, or by his standards,
fiercely shaking his head a moment ago, so maybe we should hand over to him.
Ronnie, did you chaps really start work on rhesus in this logical way, knowing
that this gene cluster might be like the butterfly cluster?
Professor Ronald Finn: Not really. I first became involved in this when I was
SHO (senior house officer) to Cyril Clarke.72 I wanted an MD thesis, and he
said to me, ‘You can work on the interaction between ABO and rhesus blood
groups’. I knew nothing about either, and I was immediately dispatched down
to the Lister, to Dr Mourant’s laboratory, to learn how to hold a pipette and
how to do blood grouping. To watch a physician holding a pipette must have
been a funny sight at the time. ABO incompatibility, in mating, is defined as
one in which the father is unable to give blood to the mother. An example of
such a mating would be an A father and an O mother. If the mother is also Rh
negative, and the fetus Rh positive, then any ABO incompatible Rh-positive
fetal cell that enters the maternal circulation will be destroyed, or inactivated,
and Rh sensitization prevented. Thus, as Professor Woodrow has already said,
Levine had discovered that ABO incompatibility between mother and fetus
protects against rhesus disease,73 and it was Race and Sanger who suggested
that the incompatible cells were destroyed and, with them, the rhesus antigen
was also inactivated in some way.74
My project was simply to provide further evidence in support of ABO
incompatibility as a protective mechanism against Rh disease,75 and I had to
carry out family studies on families with and without rhesus disease. The
important point was that working on a daily basis with ABO incompatibility
as a natural protective mechanism against Rh disease probably inevitably led us
to speculate as to whether other protective mechanisms could be devised. We
knew about ABO incompatibility. We knew the main protective mechanism
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72 Background of the Liverpool work is given in Clarke and Finn (1977). See also Zallen (1999).
73 Levene (1943).
74 See Race and Sanger (1950).
75 Finn et al. (1961); Longo (1977). See also Professor Ronald Finn’s statement on Rhesus factor at
the symposium on the role of inheritance in common diseases held at the Liverpool Medical
Institution on 18 February 1960, in Anon. (1960).
was the placental barrier, but we were on the lookout whether there was
another way of doing it. The obvious way was to find some way of mimicking
ABO incompatibility. The difference between maternal and fetal red blood
cells in this situation is that the fetal red blood cells are Rh positive and the
maternal red blood cells are Rh negative. Therefore, we suggested that an Rh
antibody, anti-D, would be expected to either selectively destroy, or inactivate
in some way, Rh-positive fetal cells without damaging the Rh-negative
maternal cells and so protect the mother against Rh disease. Thus, the
hypothesis was stimulated by ABO incompatibility. It was, in a very simple
sense, a copy or mimic of this natural protective mechanism. 
The hypothesis was then tested in Rh-negative male volunteers by injecting
Rh-positive blood to produce Rh sensitization. We tried to block it with 
anti-D. Initially we used saline agglutinating antibody or 19S, as a direct copy
of ABO incompatibility. But this did not protect. In fact, it made matters
worse and we changed to 7S-antibody which was highly successful. We initially
used high titre pooled anti-D, but later changed to anti-D gammaglobulin,
mainly to reduce the risk of serum hepatitis. The red blood cells were labelled
with radioactive chromium to study clearance, which we used as an index of
coating with antibody.76
The use of passive anti-D was, however, only part of what was called the
Liverpool hypothesis. The generally accepted view at the time, put forward by
Levine, was that fetal cells leaked through the placenta intermittently
throughout pregnancy, and he thought that sensitization could occur at any
time, probably from three months onwards. This conventional view would
mean that anti-D would have to be given on several occasions, including
relatively early in pregnancy. We were concerned that this would cross the
placenta and might cause the very disease that we were trying to prevent. We
now know, of course, that anti-D can be given safely during pregnancy, but we
did not know that at the time, and we were certainly very worried about giving
it to a very small fetus, where we might produce problems. Therefore the
second part of the hypothesis – they both stood together or fell together – was
that sensitization was usually a focal event in time, and usually occurred at
delivery. This suggestion fitted in with the work of Nevanlinna, who pointed
out that rhesus disease was unusual in the first pregnancy and suggested that
sensitization took place in the first Rh-positive pregnancy and that overt
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disease occurred in the next Rh-positive pregnancy. We had simply extended
the concept of a sensitizing pregnancy by suggesting that most significant
transplacental haemorrhages were associated with trauma to the placenta
during delivery, which was eminently logical.77 If this was correct – and this is
the main point – large doses of anti-D could be given after delivery without
any danger at all to the fetus. In order to test this hypothesis we used the
Kleihauer technique,78 which had become available about a year or so
previously, to study the incidence and timing of transplacental haemorrhage,
and it was demonstrated that most significant bleeds were associated with
delivery, although much smaller bleeds did occur, mainly in the latter months
of pregnancy. This finding supported the suggestion that sensitization usually
occurred at delivery, but the final proof would require clinical trials in Rh-
negative mothers given anti-D only at delivery, and that comes later. 
Can I finish with one or two general comments? Number one, serendipity, as
so often in research, played a large part in this work.79 We did not start off with
the intention of preventing Rh disease. Once we got involved with a protective
mechanism, we stumbled on it. Number two, the initial and critical first step
was to copy the natural protection afforded by ABO incompatibility. That’s
what the whole thing was. Again I want to emphasize that the Liverpool
hypothesis had two parts: the use of passive anti-D to inactivate the fetal cells
and, secondly, the concept of delivery sensitization.
Finally, I must say that this was very much a team effort; it involved a lot of
people over a considerable time. As Professor Woodrow, Dr Towers, and myself
are the only ones here today, I think I should briefly mention the others. Dr
Dermot Lehane was Director of the Liverpool Blood Transfusion Service. All
the male volunteer studies were carried out in the Blood Transfusion Service.
Without him, it could never have happened. Dr William Kulke provided the
chromium-labelled cells. We were very fortunate in Bill Donohoe, who was a
brilliant blood-group technician, Dr Richard McConnell was Cyril Clarke’s
chief-of-staff who monitored the whole thing. He was my MD supervisor and
he was the one who suggested the use of 7S, rather than 19S antibody when
that had failed. Philip Sheppard, whom Professor Woodrow has already
mentioned, was Professor of Genetics, and he advised us on experimental
The Rhesus Factor and Disease Prevention
30
77 Wiener (1948).
78 Kleihauer et al. (1957). 
79 See Tovey (1992). This is a recurrent theme that has come up in other Witness Seminars.
design and statistics. Finally, last but by no means least, the charismatic leader
of our team, Sir Cyril Clarke, who had the uncanny knack of making things
happen. No matter what Wiener had said, or did not say, Cyril Clarke would
have gone in this direction, I have no doubt. If Cyril Clarke had not suggested
that we work on ABO incompatibility as a protective mechanism, the whole
thing would never have happened. His remarkable journey from butterflies to
rhesus certainly deserves a place in medical history. 
Weatherall: Thanks very much, Ronnie, for that remarkably succinct
description of the long period of research. With so many interesting lessons, or
perhaps non-lessons, developed in medical research in that short story, I think
that it is worth spending a few moments thinking about some of them. May I
start off with a question, Ronnie? Why did Cyril suggest that thesis project to
you? It was pretty well known what the answer would be, wasn’t it? For
anybody outside the British scene, you should know that in those days you had
to take a postgraduate research degree for an MD, to be respectable. Why do
you think he suggested that problem?
Finn: It certainly had nothing to do with prevention, I think it was just a project
that would lead to an MD thesis. And the other point was that we could strengthen
the evidence by looking at the sensitizing fetus. In an ABO-incompatible mating,
the father could be homozygous or heterozygous, and if he was heterozygous then
the next fetus could be ABO-compatible, and, therefore, you could get a lot more
evidence to support that hypothesis if you looked specifically at the ABO-
incompatibility status of the sensitizing fetus. That was the specific point.
Weatherall: Just one more quick question before I throw this open. The kind
of serendipity of timing is always so important and the ability to identify fetal
cells in the maternal circulation is very important here. My memory is that the
Kleihauer paper came out in about 1955 or 1956, and then the paper of Alvin
Zipursky in Toronto.80 Was it his group who first actually showed the value of
it for detecting fetal cells in the maternal circulation?
Finn: Yes. It was about 1956 or 1957, and I started in 1958, so we were very,
very fortunate. As you were saying before, whatever the theory says, you have
got to have the right technology, and it came along for us just at the right time. 
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Woodrow: Ronnie Finn did part of the experimental work in Baltimore where
I followed him after a year. It is interesting to look back at the way the
experimental studies in RhD-negative male volunteers were conducted
respectively in Liverpool and Baltimore. Dermot Lehane was the key figure in
this regard in Liverpool, where his blood donors had the greatest trust in him.
It was in an atmosphere of simple altruism that the work was carried out in the
Blood Transfusion Centre or at places like Vauxhall’s factories or the
petrochemical factories in Ellesmere Port and so on. 
Such volunteers were not available in the USA where it was common practice
to use prisoners for medical research. In Baltimore the ‘volunteers’ for the
experiments were inmates of the Maryland State Penitentiary, where the liaison
was organized by Julie Krevans, head of the Johns Hopkins Hospital Blood
Bank. The prisoners used to receive, as I remember, a pack of cigarettes and
US$3 for each injection or sample of blood. This use of prison inmates was
forbidden under subsequent legislation.
Weatherall: Would you like to enlarge on just what those were? What were
you doing in a penitentiary or what was Ronnie doing in a penitentiary? What
were you doing to these ‘volunteers’?
Woodrow: The studies in Baltimore were integrated with those in Liverpool.
Groups of six RhD-negative men were injected with small volumes of RhD-
positive blood and half in each group were then given varying amounts of
plasma containing anti-D with varying characteristics, the procedure being
repeated up to four times. In some experiments survival of the 51Cr-labelled
red blood cells was measured. All the volunteers were subsequently tested for
the development of an anti-D response. In summary, it was found that plasma
containing high titres of ‘incomplete’ anti-D rapidly cleared the injected red
blood cells to the spleen and was very effective in suppressing the active 
anti-D response.
Some interesting light was thrown on the immune response to RhD-positive red
blood cells in that in some control subjects, decreased survival of the cells was
found for weeks and sometimes for months before any anti-D could be found in
their serum.81 Thus a primary response could occur without antibody being
detectable by serological methods. In others, survival of repeated injections of red
blood cells was normal and they appeared never to develop anti-D.
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May I add a little to what Ronnie has said about transplacental haemorrhage
(TPH)? Study of maternal blood samples taken immediately before and
immediately after delivery suggested that where evidence of TPH was found
after delivery, in about two-thirds of such cases this had probably occurred quite
recently. Ronnie and I looked for evidence of TPH in 398 blood samples taken
at various times during pregnancy. In 6.3 per cent of samples there was evidence
of an increase in maternal HbF (fetal haemoglobin) which made it impossible
to detect the presence of fetal cells. Evidence of TPH was found in 3.5 per cent
of samples taken during the third trimester but not earlier in pregnancy. 
Returning to the penitentiary, there was a story I heard when I went to Baltimore
after Ronnie had returned to Liverpool, that he used regularly to have his hair
cut by one of the volunteers, who turned out to be in prison for homicide.
Weatherall: Ronnie, you had better enlarge on that statement.
Finn: I was only a research fellow on an NIH (US National Institutes of
Health) grant at the time and we didn’t have much money. My hair had got
longer and longer and I could not afford to go to have a haircut, so the senior
nurse in the hospital wing where we worked in the penitentiary suggested that
she would have it cut for me. I said OK and it was very necessary at the time,
because my hair was relatively long (it’s not long now of course) and the
Americans were going through the crew-cut stage. So they locked me up in a
little cage, which was about ten or 12 feet square, with this chap who cut my
hair. The hair at that time went down the back of my neck and he got his cut-
throat razor out, down the back of my neck. He suddenly stopped and he said,
‘Do you know, they have never let me have an open blade?’ He looked like a
gangster and if he walked in here now we would all line up against the wall.
But being in Hopkins, they dealt with him. They got the psychologist to see
him, and they got the plastic surgeons to fix his nose and pull his ears back.
Weatherall: Thanks, Ronnie. Can we move back to rhesus now?
Dr Barry Benster: I wonder if I could make a very personal comment on the
use of anti-D in the prevention of rhesus disease? I’m a retired obstetrician from
West Yorkshire but, more important than that, my blood group is O rhesus-
positive and my wife Sonia is O rhesus-negative. In 1968, I was what was called
an exchange senior registrar in Malta and our daughter was born there at the
naval hospital, and I believe that my wife had the first injection of anti-D
immunoglobulin, which was flown out by courtesy of the RAF in 1968. I can’t
claim that we went on to have another 15 or 20 children, as many of the Maltese
women did at that time, but our next child was born without any immunization.
The Rhesus Factor and Disease Prevention
33
Tovey: Can I ask a question of you Liverpool people? As you know, the
Americans – Freda, Gorman and Pollack – worked on the concept that in the
presence of passive antibody the giving of the antigen prevented active
immunization in a very specific way.82 The Liverpool workers based their
researches on the concept that the fetal Rh-positive cells could be removed
from the maternal circulation; this would prevent sensitization. I would like a
comment on the fact that since we had been giving anti-D when I was working
in Leeds, we found there was no decrease in any other antibody produced by
the mothers. You would expect that if, in fact, the mechanism of protection
were by simply removing fetal cells, you would get a reduction in other
antibodies, but we never found that.83
Weatherall: Would anyone like to comment on that?
Woodrow: I am not sure whether Derrick Tovey is referring to RhD-negative
mothers who have been treated with anti-D. Of course non-Rh antibodies
would still be appearing in some RhD-positive mothers and as the incidence
of anti-Rh antibodies fell, the former would constitute an increased proportion
of all antibodies found. I am not aware of any published data that documents
the development of non-Rh antibodies in treated mothers and I would be very
surprised if their development were other than a very rare event. You will
remember the Liverpool ‘anti-Kell’ experiment in which 62 D-K- volunteers
received two successive stimuli with D+K+ red blood cells, with half also
receiving anti-K immunoglobulin. Eleven of the 31 controls developed anti-D
but only one of the 31 given anti-K did so.84 This suggested that
immunosuppression with IgG antibody was antigen non-specific. There is still
some uncertainty as to the actual mechanisms involved in antibody-mediated
immunosuppression and a very interesting seminar could be held around this.
The Rhesus Factor and Disease Prevention
34
82 Pollack et al. (1968a); Freda et al. (1977).
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Letter to Dr Daphne Christie, 1 December 2003.
84 Woodrow et al. (1975). For a review on anti-Kell in pregnancy see Leggat et al. (1991).
Weatherall: Pat [Mollison], would you like to say anything on that? Not really,
I see. So you are still arguing that after all this time the mechanism is not
clearly understood. I think it’s rather a critical point for this meeting.
Dr Patricia Tippett: When I was working in Boston in the 1950s, they were
trying an immunological protection by desensitizing the women who had lost
affected babies. Dr Allen was injecting his own Ro blood (Rh-positive
phenotype) which he knew was OK and he hadn’t had jaundice or anything.
This, of course, didn’t succeed in protecting any of these women, but there was
one case where a woman made an additional unrelated (anti-Kidd) antibody. 
Dr Belinda Kumpel: Just a quick word about the anti-D or the mechanism of
immune suppression that may be happening. It’s not really known for certain,
although earlier on in the 1960s and 1970s there were some nice experiments
done on rabbits85 by several of the people here, and since then on mice as well.86
However, none of the experimental animals are suitable models for Rh-D. This
is because Rh-D negative people lack the whole molecule as they do not have
the Rh-D gene, whereas rabbits have a true polymorphism of a blood group
and make allo-antibodies. Mice have no blood groups. So xenogeneic cells are
used, usually sheep red blood cells, and both the antibodies that are formed are
different. In mice it’s usually IgM. The timing of antibody appearance suggests
the mechanisms are different in the three situations as well.87 So it is very
difficult to actually solve it with humans,88 because you can’t ask for samples of
spleen from volunteers, which is what would be required.
Zallen: I would like to ask about the comments that Cyril Clarke made that
this was a group of amateurs.89 Was the team really such a group of amateurs?
Did they start as amateurs and become more polished researchers? 
Weatherall: Perhaps we had better hear from both of them. We might then get
some kind of balance.
Finn: Cyril Clarke always described himself as an amateur scientist, and I think
that fitted in with us at that time. The main point was that we weren’t involved
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in Rh or blood group work; we weren’t from the laboratory; we weren’t blood
transfusion people; we weren’t paediatricians; we weren’t obstetricians and we
weren’t immunologists. So we were completely divorced from the ordinary way
of doing things.
Weatherall: If that’s not a good definition of an amateur, what is?
Finn: But in a way often that is better because, if you are coming from
completely out of the field, you can think laterally, whereas people within the
field find it much more difficult.
Weatherall: Pat, what did people who were really in the field think in the early
1960s about this approach?
Mollison: Well, I don’t think they were confident it was going to work.
Weatherall: Why?
Mollison: Just general scepticism, I suppose, not very rational. I think
everybody accepted the idea that ABO incompatibility prevented or
diminished the chance of Rh immunization. I don’t think there was general
confidence that immunosuppression using anti-Rh was going to work, and I
don’t know why that was.
Weatherall: Johnnie [Woodrow], did you want to comment on the
amateuristic atmosphere in your laboratory at that time?
Woodrow: That is a rather complex question. The technology was pretty
unsophisticated but we had an excellent serologist in Bill Donohoe, and those
involved in the fetal cell counts went to great pains to make the method as
accurate as they could. The experimental design of the experiments was far
from amateurish. I am always struck when I go back to the published papers
(and this also applies to the ‘blood groups and disease’ studies) by how
carefully and generally well-written they were and they certainly do not read as
the work of amateurs. The people involved differed from each other in various
respects as was to be expected and it was the great achievement of Cyril Clarke
and a tribute to his powers of leadership that they worked so well together over
a period of several years. It is also important to put on record here the
contribution of Féo Clarke who was involved with Cyril’s work at every level
and who was, I am sure, an indispensable collaborator in all aspects of his
research activities.90
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Finn: I would certainly agree with that. She was a remarkable lady. In her
eighties she went to the Open University and learnt to speak Russian so that
she could read Russian novels in the original language. Just to follow on from
Professor Mollison, I think one of the reasons there was such great scepticism
was we were altering completely the natural history, or the view of the natural
history, of rhesus disease, and the thing was even if the anti-D worked, when
would you give it? This concept of delivery sensitization took a lot of
accepting. I think that was one of the problems. 
Scott: It was the creation of the Cyril/Féo combination that was vital to the
whole story.
Weatherall: I will tell you more about that during the interval.91
Dr Frank Boulton: I came on to the scene very late. I came to Liverpool in the
mid-1970s, and was a registrar at the London in the early 1970s. It was from
conversation with John Jenkins, and from his reminiscences (by that time it
was all established) that I think that people were very afraid for the baby. There
was a lot of concern that giving something to the mother might continue to
make the baby even worse. So I think that’s just one little point 
of reminiscence. 
The other question, which I think Belinda [Kumpel] was hinting at a little bit
though, is why did the 7S work and not the 19S? Indeed the IgM even seemed,
Ronnie, to make it worse from what you say. Have there been any thoughts
about that?
Finn: I don’t think we know. Professor Mollison may wish to comment?
Mollison: I think that IgM antibodies which don’t bind complement, like 
anti-D, have never been shown to destroy red blood cells in vivo, and therefore
it’s difficult to believe that they are concerned here. With Nevin’s help, we
purified IgM anti-D and tried in volunteers to see whether it would suppress
immunization. Although at the time we concluded that IgM had destroyed red
blood cells, later on it seemed to me much more likely that the IgM
preparation was contaminated with a small amount of IgG, and that this was
what had produced the effect. We couldn’t have detected the amount of IgG
antibody that was there, but we worked out that there could have been
enough. So returning to the Liverpool experiments, I don’t think that the IgM
preparation they used, the agglutinating anti-Rh, was responsible for the
The Rhesus Factor and Disease Prevention
37
91 Further discussion of the importance of Féo in Cyril Clarke’s work is found in Weatherall (2002).
increased number of responders. I think it is conceivable that it was the same
case as with us, that there were traces of IgG anti-D there, which augmented
immunization. There is, in fact, some evidence that very small amounts of IgG
anti-D when given with red blood cells do actually augment the response,
although I think you have to say that the case is not proven. There is no
completely convincing explanation of why in Liverpool they found that giving
agglutinating anti-Rh apparently increased the number of responders. I think
this is a mystery.
Professor Peter Harper: As one who came in from the outside to work with
Cyril Clarke and colleagues in Liverpool in the later part of the 1960s, I would
like to come back to this question about a group of amateurs. I think that the
group as a whole, and Cyril in particular, were far from being a group of
amateurs. They were outstandingly talented, and I think the reason why, or
perhaps one of the reasons why they were able to take a step that hadn’t been
taken by others more immediately involved, was just that. They were able to
stand back from the immediate and specific aspects of the field, whether this
be serology, or paediatrics, or obstetrics, and look at it as a kind of research
problem from first principles. Cyril, in particular, was very much a person of
first principles. Because of his basic experience in genetics, partly through his
links with Philip Sheppard, he was able, I think, to move from one situation
to another in a way that perhaps people more immediately involved in the
applications were not. 
People are often a bit disparaging about the butterfly work, but in fact it is
strikingly modern. Workers in genetics use model organisms all the time, and
now in human genetics one shifts, as indeed Cyril did then, between one species
and another without much trouble. We know the genomes are all very similar. I
think Cyril may have chosen butterflies as a rather unorthodox model organism,
and I am quite sure one of the reasons he chose them was because they were more
enjoyable than something like Drosophila to work with. But they were very
valuable nonetheless. I think he was able to approach this problem from the
point of view of theory, as Ronnie Finn has said, and look at it very broadly and
I don’t think there was any ‘amateurism’ meant in a disparaging way. There was
extraordinary ability of the research design and original thought, and Cyril
imparted that to all the people who were working with him. 
Dr Peter Hunter: Two points. One about lateral thinking and another about
the wives of clinical scientists. In the genesis of serious innovations in medicine
in the twentieth century, and particularly treatments, lateral thinking has been
The Rhesus Factor and Disease Prevention
38
extraordinarily important. Although we now accept that it is easy to treat
schizophrenia, psychiatrists played no part whatever in the origin of the
treatment of schizophrenia, which was actually created by the people who first
made drugs like largactil which were then used by a military anaesthetist in the
armed forces of France as part of a system for preparing patients for operation.
The doctor involved, Henri Laborit, suggested to psychiatrists in Paris that
drugs like largactil should be tried as a type of sedative for a variety of
psychiatric disorders.92 When the first patients received them, the results were
so startling that the nurses couldn’t believe their eyes. 
The second point is about the influence of wives of great clinicians. There is a
longstanding tradition that biographies are called, for example,  ‘Marlborough,
His Life and Times,’ I think in some cases serious consideration should be
given to the title, ‘Dr X, His Life, His Wife and Times’. 
Dr John Silver: It is with some deference that I speak like the spectre at the
feast of the amateur approach at Liverpool. All has been portrayed as sweetness
and light, but it was an extraordinary experience coming to work in Liverpool.
I was appointed in 1965 to work in Liverpool as Consultant-in-Charge of the
Spinal Injury Service for Merseyside, and some days before I was due to move
to Southport I got an approach from John Goldsmith (renal physician), who
suggested that I wouldn’t have enough work running the spinal unit, and I
should take on the chronic dialysis programme for the whole of Liverpool. I
was a bit surprised. I had just put down my mortgage in Southport and I
thought I would have more than enough to do to run the spinal injury service
for Merseyside single-handed. Anyway, after some weeks I went across to see
John Goldsmith and was delighted and surprised to see the renal physician
who had been appointed: Ronnie Finn. It was an extraordinary kind of
atmosphere, especially the way we plan today, to think that you could be
appointed to one post and just al fresco take over something like the chronic
dialysis programme for a whole region. Of course I didn’t, and I think Ronnie
Finn did, but I would like to know, with some deference, was your experience
of renal disease the same as mine?
Weatherall: I am not sure we should embarrass Ronnie in public by answering that
question [he had no comment]. Can I ask an alternate question, Ronnie, because
it is getting close to tea, and I had to review all Cyril Clarke’s work recently? I came
across that extraordinary article in the Scientific American, an autobiographical
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account,93 where he clearly states that the first concept in your group to give
patients anti-D arose when his wife Féo woke from a deep dream in bed and
shouted at the top of her voice ‘give them anti-D’. Ronnie, you probably were the
closest to that, do you think that there is any possibility that that was true?93a
Finn: David, I thought this might come up and I had never thought about it
before. But three or four days ago I thought I had better put my mind to it, and
I think it could well be true. I don’t think Cyril would ever tell a lie. My hypothesis
is that at the meeting of the Medical Institution in Liverpool in February 1960,
when I first mentioned that we might consider preventing rhesus disease with
anti-D, this was a throwaway remark at the end of the paper. It was a symposium
on medical genetics in which there were five papers within a two-hour period, so
it was all pretty rushed, and the rhesus paper was in the middle and it was just one
throwaway remark at the end of it. My hypothesis is that it didn’t register with
Cyril at all; he didn’t hear it. But then the next thing that would have happened
is that Cyril decided to write this up, which eventually became terribly important
because it gave us priority over the New York group. That’s why it became
important, but at the time it wasn’t of course. And Cyril and Féo used to write
things up together, but I suspect that very often Cyril said, ‘I am busy today, Féo,
you write it up’. Then Féo would have come across this sentence about preventing
Rh haemolytic disease, and, being Féo, she would have thought about it and
worked out what it meant, and then she would have told Cyril. It might well have
been in the middle of the night, but as you know Cyril went to bed very early, so
it could have been in the middle of the evening. The other point, of course, is that
the report in the Lancet simply said that Rh disease might be prevented by the use
of a suitable antibody. I looked at my typescript notes the other day, and that’s
what it said. Some people say that I used the word anti-D or rhesus antibody at
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the time. I don’t remember whether I did or I didn’t and we just don’t know. It is
possible that Féo actually worked out what the antibody was. So I believe that the
first time Cyril did hear the idea was from Féo. That’s my hypothesis.
Weatherall: I think I see the new Director of the Wellcome Trust sitting here,94 and
I hope coming in at the end of this conversation he has now got a clear idea of how
to plan the future of really important science. I think we had better break for tea. 
We left off the story when the preliminary clinical trials, or the experimental
study in human ‘volunteers’, provided what is called these days a ‘proof of
principle’. What we need to know from the Liverpool group, and I hope they
will tell us a little bit along the way, is what was happening in New York.
Johnnie Woodrow’s going to introduce this and we have got several people here
who are absolutely key in those trials, so it will be extremely valuable. John,
would you like to kick off?
Woodrow: The clinical trials, following the events that Ronnie Finn told you
about, started in May 1964.95 RhD-negative primiparae who gave birth to RhD-
positive ABO-compatible babies were entered into the trial. As there was still
uncertainty about certain aspects of the natural history of Rh immunization by
pregnancy, the opportunity was taken to study the control mothers carefully in
order to learn as much as possible about this. It was confirmed, for example, that
when a primary immune response occurs as the result of a stimulus of RhD-
positive fetal cells late in pregnancy or during labour, this may manifest in some
women by the appearance of anti-D in the subsequent months but in others
antibody is not found until the later months of the next RhD-positive pregnancy,
in most cases due to a second stimulus. It was found that the larger transplacental
haemorrhages seemed more likely to induce an immediate antibody response,
while the smaller stimuli were less likely to do so but more likely to induce
priming without detectable antibodies. It was therefore decided that the success
of immunosuppression by anti-D would be measured in the first instance by
testing for anti-D six months after delivery, and that the mothers would be
followed up and tested again at the end of the second RhD-positive pregnancy. 
The Rhesus Factor and Disease Prevention
41
94 Dr Mark Walport was a Governor of the Wellcome Trust for two years and was appointed Director
on 1 June 2003. Sir David Weatherall retired as a Governor of the Wellcome Trust in 2000. 
95 See Mollison and Walker (1952). Professor John Woodrow wrote: ‘The work books recording the
day-to-day entries in the clinical trial together with those documenting the experimental studies in
the male volunteers in Liverpool and with other relevant documents including correspondence, are
deposited in the Special Collections and Archives, Sydney Jones Library, University of Liverpool,
referenced 530.’ Note to Dr Daphne Christie, 27 November 2003. 
The first trial involved mothers thought to be at highest risk, that is those
whose fetal cell count after delivery indicated approximately 0.2 ml of fetal
blood in the maternal circulation. Approximately 1000 mg anti-D
immunoglobulin was administered to alternate mothers after delivery. This
trial was conducted in collaboration with centres in Sheffield, Leeds and
Bradford, and Baltimore. Thirty-eight of 176 control mothers and only one
out of 173 treated had detectable antibody at six months. This represented a
97 per cent reduction in immunization at this time. On testing at the end of
the second RhD-positive pregnancy, 20 out of 65 control mothers and two of
88 treated had anti-D, a reduction of 93 per cent. 
A second trial was later commenced in Liverpool which included the women
who had not been included in the first, that is, those whose fetal cell count
suggested less than approximately 0.2 ml of fetal blood in the maternal
circulation. A single blood sample taken immediately after delivery does not in
all cases tell one how much fetal blood has entered the maternal circulation.
For example, when there has been a small transplacental haemorrhage in the
weeks prior to delivery which has induced priming, followed by clearance of
the fetal cells, there may be none present at delivery. This is one of the
explanations for the occasional failure of anti-D to prevent immunization in
mothers whose blood sample after delivery had shown no fetal cells. The
treated group were given 200 mg anti-D. 
Tests six months after delivery showed 13 out of 362 of the controls to have
anti-D compared with none of the 353 treated mothers. At the end of the
second RhD-positive pregnancy, 13 of the 127 controls had anti-D as against
three of the 128 treated mothers. This represented a 78 per cent degree of
protection. The confidence limits here are wide, and when more treated
mothers were followed up, this figure rose to 90 per cent. In some instances the
appearance of antibody in the pregnancy subsequent to the treated one may be
due to primary immunization and thus only preventable by antenatal anti-D. 
Weatherall: John, thank you very much. Ronnie or Shona, do you want to add
anything, or Nevin, who was very much involved at that stage? 
Finn: I personally took no part in the clinical trials, but I watched the results,
obviously with great interest, and one of the things that surprised me was the very
high success rate. If we were relying purely on delivery sensitization, which was the
original hypothesis, we should have had a success rate of probably 70 or 80 per
cent. So I don’t think that delivery sensitization is the whole story, and I think it’s
likely that there is some form of depression of the immune response during
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pregnancy, and there’s a lot of clinical evidence of this. Things like SLE (systemic
lupus erythematosus) will get much worse after delivery and so on, and we did do
some studies looking at lymphocytes in pregnancy and mixed lymphocyte
cultures between mother and fetus and they were in fact diminished, down, in
pregnancy. So the remarkable results of delivery treatment suggest that this thing
is a little bit more complicated than just the cells coming over at that time. 
Mollison: I think one should mention that by a lucky chance Nevin [Hughes-
Jones] produced his method of quantitating anti-D in 1967.96 Up to that time,
all these early experiments were done on titre, which is not very reproducible,
and it is very difficult to compare one sample with another. So it was very
fortunate that this came out at that time and it was possible, as you may
remember, to have control trials of dosage in this country two years later; the
effect of different doses was compared, and that would have been impossible
without a quantitative method. I was very happy that it happened at that time.
Dr Nevin Hughes-Jones: The agglutination method was incredibly inaccurate.
In some surveys that we did, you would get about 100-fold difference, with
different people doing titres. So that the only contribution made by that
measurement, in terms of micrograms, was that by radioactively-labelling the
anti-D molecule, it did make the assay more accurate.
Weatherall: Dr Bangham is with us, who was involved with this.
Dr Derek Bangham: First let me explain that I am a medical innocent of
specialized haematology. My career has been concerned with biological
standardization – the characterization and measurement of biological
substances important in clinical and research medicine. This was the
responsibility of the Division of Biological Standards at the NIMR (National
Institute for Medical Research), and since 1972, by the NIBSC (National
Institute for Biological Standards and Control).
Yes, we ran a study to assess the accuracy of that method (which was believed
to measure milligrams of anti-D immunoglobulin) in assays of coded samples.
When Nevin Hughes-Jones learned of the international approach he then
readily collaborated with us.
The long-proven procedure is to prepare a large batch of selected material,
ampouled in stable form, against which other preparations can be assayed in
appropriate comparison biological methods. A pool of sera from naturally
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immunized multipara was provided by the Blood Products Laboratory at
Elstree by Bill Maycock. This was freeze-dried in some 2000–3000 ampoules
at NIMR. An international collaborative study was run in which coded (that
is, unknown) ampoules of this and several other preparations were assayed by
23 expert haematologists in 11 countries.97 All their raw data results were
analysed statistically at NIBSC. The report of the study was accepted by the
WHO Expert Committee on Biological Standardization and the ampouled
material was established in 1976 as the First International Standard for 
Anti-D Immunoglobulin, to define the International Units of activity. This has
stood for 30 years and is only now being replaced.98
Various attempts had indeed been made to convert haematologists from stating
their estimates of blood-typing sera in terms of ‘titres’ of their local serum to using
international units by assays against a standard properly calibrated in international
units. When commercial preparations (for example, anti-D) became licensed for
clinical administration, it was essential to have attested the internationally
accepted methods with which to control their potency and quality.
I am explaining all this to set the record straight and show how research on
assay methods is evaluated internationally. So this is another example of
biological standardization in which this country has led intellectually,
scientifically, and in hard practice. Britain now looks after almost all
international reference biologicals.
Weatherall: I just wonder, while we are on the subject of international
collaboration, we have not said much about the Freda and Gorman team in
New York who were racing you, if it was a race. I don’t know if John or Ronnie,
or any of you, would like to say a brief word about the American enterprise,
and how interactive it was with the Liverpool group.
Finn: I first found out about it when I went to see Philip Levine, when I was
working at Hopkins, and he said you must go up and give a seminar at
Columbia on medical genetics, and I got there and gave the seminar. At the
end of it, three young men [John Gorman, Bill Pollock and Vince Freda],99 my
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age at that time, came along and asked a lot of questions, and said, ‘We are
doing similar work’. That came as a complete surprise to me. But it became
obvious that they were also working on it independently, but using a different
theoretical concept. And, as we said before, it hasn’t finally been worked out
which one is correct. 
The other thing that they did at that time was that Bill Pollock from Ortho100
gave me a specimen of the gammaglobulin, anti-D gammaglobulin, which I
used. Relations between us at a personal level were very good. Of course, John
and I both worked at the Hopkins for a time, so Julie Krevans in the blood bank
there played a part in this as well. Relations were good. I don’t think we, at our
level, ever really thought about it as a major race. I don’t know what John thinks.
Woodrow: I fully agree with Ronnie. When I was in Baltimore I paid several
visits to John Gorman in New York and there was always a pleasant and free
exchange of ideas and experience. Everyone wanted the work to go well. I
remember an excellent conference on Rh prophylaxis organized by Bill Pollack
at Princeton. You will recall that John Gorman had come from Australia to
work in the Columbia–Presbyterian pathology department and spent much
time in the blood bank. He was browsing through a general textbook of
pathology and came across a reference to Theobold Smith, who in 1909 was
working on the induction of immunity with diphtheria toxoid.101 He had
found that if too much antitoxin were given with the toxoid, active immunity
failed to develop. This drew John’s attention to the possibility of
immunosuppression by antibody. Even prior to this, two pupils of Paul Ehrlich
had reported in 1900 that if ox red blood cells were injected into rabbits an
antibody response resulted but if specific antiserum were given with the red
blood cells, the antibody response did not occur or was very weak.102
Weatherall: I remember talking to John Gorman. They got held up at the
beginning because they had trouble persuading the NIH that this was worth
supporting. Then I thought, from my memory of the Liverpool days, that this
must have been the most shoestring research ever done. You just paid for a 
few Kleihauers. 
Finn: I am not aware that any grant at all was given for it. Registrars worked
for nothing; the technicians, Bill Donohue was working in the department;
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and all the work done at the Blood Transfusion Service was voluntary. I think
it was done on a shoestring. 
Zallen: When did the Nuffield Foundation grant come?103
Finn: That came much later, when the clinical trials were starting. 
Weatherall: So this whole programme and all the basic work was done
without one grant. I think that probably is worth recording.
Rodeck: I would say that in all likelihood this so-called bunch of amateurs, if they
had applied to the Wellcome Trust for funding, would have been rejected. 
Weatherall: (I think the new Director has left, hasn’t he?) Any other
comments or questions or queries about that critical period of clinical trial? It
is a wonderful story and the results, compared with most clinical trials, were
devastatingly good, weren’t they?104 Quite extraordinary. In the short time that
we have got left, we have two other items before asking Pat Mollison to put the
Rh locus into its present perspective. It would be helpful, I think, since we
didn’t have the chance earlier, to have a very brief update on what’s happened
on the structural side and our knowledge of the locus, and also, presumably as
the number of folk with anti-D naturally declined, what’s happened since in
terms of monoclonal antibodies and current questions of availability of anti-D
and so on. Did your success actually create problems? Is David Anstee here? Yes.
You have several of your colleagues here and there have been major advances in
our understanding of the rhesus system since we left off in about 1960. 
Professor David Anstee: The critical experiments that opened up the route to
identifying the structure of the protein were made by Stephen Moore, who
worked in the Edinburgh centre of the Scottish Blood Transfusion Service,105
and at the same time independently by Carl Gahmberg in Helsinki in 1982,
when they showed that they could immune-precipitate the Rh proteins.106
Having identified the proteins, then it was a question of applying the existing
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technology to obtain enough of those proteins for some amino acid sequence
determination and then to isolate cDNA.106a At about the same time,
monoclonal anti-D was becoming available from the culture of B lymphocytes
transformed with Epstein-Barr virus. Nevin was involved in that work in
Cambridge, and Belinda Kumpel, who is also here, in Bristol. They provided
enough antibody to purify sufficient protein for sequence characterization. So I
think it was about 1990 when that process produced full-length cDNA for the
first of the Rh proteins. That was obtained in Jean-Pierre Cartron’s group in Paris
and in our own group by Neil Avent, who is sitting in front of me.107 So we had
amino acid sequence for one of the Rh proteins derived from the cDNA
sequence. By that time, we knew that there were at least two Rh proteins from
immune precipitation studies. Subsequently it emerged that there were two
genes: one that encodes D and the other that encodes C and E. I think that’s
rather a satisfying result, following on from the discussion earlier about the
disagreement across the Atlantic between the Wiener hypothesis that there was
one gene and the Fisher–Race hypothesis that there were three genes, because the
right answer turned out to be there are two genes and so they were both wrong. 
That characterization in 1990 established the nature of the proteins that give
rise to the antigen and since then a great deal of work has been done to
characterize the nature of the polymorphisms that give rise to the variety of
antigenic structures upon those proteins. I think that was the critical phase: the
identification of the molecules themselves by Stephen Moore and Carl
Gahmberg originally, and then the cloning of the genes around 1990. D was
cloned around 1993, the first cDNA sequence encoded the product of the CE
gene. These findings formed the basis for all the work that has gone since.
Professor Neil Avent: I was involved in the cDNA cloning. Gene structures have
been purported to be correct as the two Rh genes, which are in reverse orientation
to each other, are on chromosome number one. If you look at some of the recent
Sanger contigs, they don’t actually totally agree with that idea. So the idea that the
human genome sequence is complete, I think, is premature, especially in Rh
genetics. So there’s a little bit of work to be done looking at the correct orientation
of the Rh genes and I think that this may vary between different Rh genotypes. If
you look at one of the Sanger contigs, it encodes the big CE protein, which we all
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know is extremely rare and very unlikely. On a closer analysis it is half of a RhD
gene and half of a RhCE gene (Rh-D, Rh-CE). So this contig is not correct. I still
think that more work is needed to look at the genomic arrangement of Rh genes
in different Rh genotypes and work out what precisely is going on, because I don’t
think it’s the end of the story yet, in terms of Rh genetics. 
Weatherall: What’s the function of the Rh antigen?
Avent: Some work done by Ann-Marie Marini in Bruno André’s lab in Belgium
has indicated that they are very closely related to ammonium transporters in
lower organisms.108 There is some direct evidence that they are involved in
ammonium transport. Yet other work in the New York Blood Center has shown
that Rh protein expression is elevated in response to high CO2 levels in green
algae.109 So there is some possibility that Rh proteins are involved in CO2
transport as well as another gas transporter on the surface of red blood cells. The
jury’s out really, in terms of what the precise functions are. Ammonium
transporters may be involved in CO2 transport, but Rh-null individuals
109a have
deficiencies in all Rh proteins on the surface of their red blood cells, so the
function isn’t absolutely critical. Clearly there are other proteins in red blood cell
membranes that transport CO2 as well. So there’s probably a dual role for Rh
proteins at the moment, but the final picture isn’t there just yet. 
Weatherall: Thanks very much. Any questions or comments about this?
Professor Ian Franklin: Is there any advantage in being rhesus-negative or
positive on a population basis? Why is there such a clear polymorphism?
Kumpel: If you are a fetus, maybe it’s an advantage to be rhesus-negative, because
then your red blood cells can’t get destroyed by anti-D. It is not yet known how
rhesus-negativity emerged, because it’s only in Caucasians that the gene is lacking.
There’s a pseudogene in Africans. It’s really a question for another afternoon I
should think, because it’s only arisen in whites and not in blacks or Asians.110
Avent: I think Belinda is right. The point was initially made by Peter Agre at
Johns Hopkins and Jean-Pierre Cartron in Paris. The D-negative phenotype
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probably did arise as a response to haemolytic disease and the fact that you had
a benefit in being rhesus-negative. It has arisen as two different genetic
polymorphisms: the Caucasian D gene deletion and the black D-negative
phenotype that is due to a mutated Rh-D gene. So there are two separate ways
of being D-negative and there are many others that we know of as well. So
about 7 per cent is D-negative in black populations and 15 per cent in whites.111
Weatherall: This is a kind of general situation with a lot of blood group
genetics at the moment. The mechanisms for variation are still, to put it
mildly, very speculative, but it’s going to be a very interesting story I think.
Now to get back to the practicalities. Before I ask the fetal medicine folk to
summarize the impact they think all this has made on fetal medicine, could
you update us on the management of the prophylaxis over recent years in
terms of the role of monoclonal antibodies, source of anti-D material, and so
on? Where do we stand at the moment?
Anstee: There has been a programme for more than 15 years to develop and trial
monoclonal anti-D as an alternative to the use of polyclonal anti-D. Studies in
male volunteers have shown that monoclonal anti-D is effective.112 This
programme is still going on at the Bio Products Laboratory (BPL), Elstree.112a But
the availability of anti-D from immunized volunteers, as I understand it, is not a
problem at the moment, and indeed, the material that’s being used in this country
is fractionated from plasma, from anti-D donors, purchased from the USA. I
think there hasn’t been pressure to push the monoclonal antibody product
because the availability of the conventional product is not limiting at the
moment. There was a period when availability of anti-D in this country was a
problem, but that was when we were using our own donor material to provide the
product, in a drive for self-sufficiency for such products. However, the decision
was made to source plasma from outside the UK (in response to the crisis over
variant Creutzfeldt-Jakob disease), and since plasma was being purchased for all
products, anti-D could be purchased. So what’s happened at the moment, as far
as I understand, is that there is no shortage of polyclonal material for
fractionation. The cost of bringing the human monoclonal alternative to market
is extremely high. The absence of real pressure to provide a product when it is not
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a problem to source it through the conventional route, has taken the drive away
from delivering the monoclonal product. So it’s there, and it’s going through
clinical trials, but it’s not available yet. 
Tovey: When we had to produce a lot of anti-D from our own resources, this
produced a major problem in Britain, because obviously our main source was
mothers with antibody, and that was decreasing with the success. There were two
procedures that helped us to tackle this problem. First of all was the introduction
of plasmapheresis.113 This meant taking a donation from a donor with high levels
of antibody, centrifuging it, removing the plasma and returning the red blood
cells to the donor. This was then repeated. Thus, we finished up with two
donations of valuable plasma. Later this technique could be performed by a
machine, a technique pioneered by my colleague, Dr Angela Robinson.114
The second way was deliberately to immunize Rh-negative male volunteers, and
this was obviously an ethical dilemma. One was proposing to inject ‘foreign’
Rh-positive cells into these volunteers, bringing with it the rare but possible
transmission of disease (for example, HIV) or the development in these
volunteers of other blood group antibodies or white cell antibodies. As I will
explain later, we did everything possible to avoid these complications, but we
could not guarantee 100 per cent protection. However, in many centres we did
succeed in obtaining considerable numbers of male volunteers and, as far as I
know, there has been only one case that has caused problems. That was a very
unfortunate case where a man, years later, developed renal failure, and
unfortunately he couldn’t have a kidney transplant because of the white cell
antibodies he had developed, obviously most likely as a result of the
immunization. The donor red blood cells were chosen from donors who had
donated at least 40 times and the patients receiving their blood had suffered no
ill effects. The red blood cells did not contain antigens such as little c or Kell,
which often cause antibodies to develop, and the cells were washed to remove
white cells. So, over a long time, we did our best in Britain in order to raise
enough anti-D to allow not only post-delivery prevention, but also antenatal
prevention. But I think it should be recorded that over this long period of time,
a considerable number of Rh-negative men, in spite of the possible
complications, were prepared to be injected with a foreign substance, in order
to help Rh-negative women – truly altruistic acts, as they received no payment. 
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Franklin: It is just worth pointing out that in the USA the reason they have no
problem getting their supplies is that they pay donors the going rate. I have to
say as a clinician I think it is unfortunate that there hasn’t been a move towards
a successful monoclonal antibody. One other interesting point about, I think
it was Ronnie Finn, who changed the formulation to avoid serum hepatitis.115
I suppose there are always going to be question marks over allogeneic blood-
derived products, and I think a monoclonal product would be infinitely
preferable, as far as I am concerned.
Dr Angela Robinson: I would like to comment on the development in the
clinical trials of the monoclonal antibody. Last week I was at the Bio Products
Laboratory where they were telling us about these trials with a recombinant
monoclonal antibody. The big difficulty is that the times are so different.
Imagine the size of the study that would be required to get it through the
European Committee for Proprietary Medicinal Products (CPMP),116 which is
the European regulatory committee, and the ethical problems of using this
unknown substance in pregnant women. You couldn’t choose a more difficult
trial to undertake. The numbers that they want, to give the study sufficient
statistical power to prove effectiveness, are just so huge. It’s almost certainly
beyond BPL’s ability to fund without some collaboration with a huge
commercial partner. It’s very sad that the times are such that where you could
have done this study in Finn’s day, it’s proving almost impossible to do it today. 
Mr Ian MacKenzie: There is, however, a need to develop a recombinant
monoclonal product because, in today’s climate, patients want to know the risks
they might be letting themselves in for, and with the recent NICE (National
Institute for Clinical Excellence) guidelines, all non-sensitized rhesus-negative
women should be offered antenatal prophylaxis.117 I know from experience of
trying to recruit women to trials, they are very reluctant to take part in a study
that involves a blood product, because of the risks that exist. So there is a very
big drive to develop a recombinant monoclonal product. 
Dr Edwin Massey: It’s interesting. At huge cost, the haemophilic treatment in
the UK has changed in the last few years.118 In Wales, a recombinant factor
VIII and factor IX have taken over completely from human plasma-derived
factors. The same is now being undertaken in England. You would have
thought that there would be a strong impetus to be doing the same for
pregnant women with anti-D.
Kumpel: I would like to say that we all know how effective the polyclonal
product is, and it has been proved to be extremely safe by nearly all the
manufacturers. There’s no reason why the monoclonal shouldn’t be so as well,
and you understand the concerns of the regulatory authorities in producing a
medicine for healthy women during and after pregnancy. The only worry that
I would have is that most of the European countries and some of the smaller
countries don’t manufacture their own anti-D because of the expense, so that
most of it is now purchased from North American sources. If there was any
compromising of the supply from North America, either a new virus or
something or another factor that reduces the supply, then there is nothing in
the pipeline as a reserve. The monoclonal is not yet ready and most other
countries can’t come up with their own. If there’s not enough antibody, we
know we will be back to the situation in the 1960s where there will be deaths
from haemolytic disease, well, possibly not deaths, but it will be a severe
problem for the obstetricians and I think it’s a shame that the regulatory
authorities do have to be so stringent in producing an alternative supply.
Finn: May I mention something that is highly speculative? At the very
beginning we decided purely empirically to pool our sera together. I don’t
know any scientific reason for this but, empirically, if you mix them all
together you are going to get a broader antigenic coverage. My understanding
is that a monoclonal antibody has been tried in experimental circumstances
and found not to be very effective. What I am going to suggest is that if you
do eventually make monoclonal antibodies, they should be mixed together
afterwards and not simply rely on a single monoclonal. I don’t know whether
that is nonsense, but it’s just a thought I’ve had. 
The Rhesus Factor and Disease Prevention
52
118 See Tansey and Christie (1999): 35, 75–7. 
Anstee: Just a point to clarify that the monoclonal product that’s been
developed at the Bio Products Laboratory is a mixture of two monoclonal
antibodies. So it’s not just a one shot. Although I think there is some evidence
that if you have the right antibody one will work. To make a product
comprising a large number of different monoclonal antibodies would add
greatly to the cost of the development programme.
Weatherall: I think we have given that enough fresh air. All medical advances
produce another set of problems, but they don’t sound insurmountable. We
should ask Timos Valaes and Charles Rodeck if they would like to say a few
words on the total impact of this on fetal medicine. Somebody asked me in the
interval if you could mention phototherapy along the way, because it’s
something that we have neglected a bit this afternoon. It is the one form of
treatment that we haven’t explored.
Valaes: The impact, as far as the neonate, was completed by the mid-1970s. By
that time, almost all babies born alive and not extremely immature or hydropic
would survive intact. Phototherapy helped in reducing the number of
exchange transfusions necessary to keep serum bilirubin at a safe level.119 From
our vista as neonatologists, we saw the whole battlefield being transferred from
treatment of the neonate to in utero interventions to improve the chances for
survival of the fetus. As I said before, these efforts were evolving against the
backdrop of diminishing numbers of isoimmunized pregnant women as the
result of the preventive programmes. At the same time, neonatology and fetal
medicine have exploded in their techniques to take on other big problems. I
don’t think we are going to see many isoimmunized women. Seldom there will
be lapses in the preventive programmes or failures of anti-D globulin
prevention because of a large feto-maternal transfusion that was not detected
and the dose of anti-D was not adjusted accordingly. 
Rodeck: That’s not quite our experience. There has, of course, been a major
reduction in the incidence and prevalence of women with antibodies, but we
still have, as do most fetal medicine units, a couple of women on the go at any
time with antibodies, and we would still be doing about 30 transfusions a year.
These are on average a couple a month, which means there is a serious risk that
this will lead to more operators becoming deskilled. But we have left the story
I think, with Liley’s intraperitoneal transfusion, and of course that didn’t help
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the very early, very severely affected fetus that was hydropic because of poor
absorption of the transfused blood. Liley was given the idea by a paediatrician
from Africa, who had gone through his unit, who said that’s how they
transfused their sickle cell children. The basis of this transfusion is that it gets
absorbed from the peritoneal cavity into the lymphatics and then up the
thoracic duct and into the circulation. Hydropic fetuses don’t absorb this, so
that you have the paradox of the most severely affected fetuses not actually
benefiting from that treatment. In the 1970s a whole variety of techniques
were coming together, which enabled and increased activity in intrauterine
intervention, and there was a lot of interest in fetal blood sampling and that
was partly the fault of our chairman, Professor Weatherall, who devised a
technique for the diagnosis of haemoglobinopathies, and so a lot of us were
interested in that area. Humphry Ward and Ian MacKenzie, in this room, were
involved in that too. At that time, at King’s College Hospital, London, we were
developing a fetoscopic method for obtaining fetal blood, which resulted in
pure samples from the umbilical cord, and if you could take out blood from
the cord, it meant you could put in transfused blood as well. 
But our problem was that we couldn’t get hold of any rhesus patients. They
were all at the Rhesus Centre at Lewisham Hospital and were guarded
jealously. I happened to be in Oxford giving a talk and returned on the train
to London with David Whitmore, who was a haematologist from Lewisham
(he was part of their impressive multidisciplinary group). I said to him, ‘This
is a blood disease, wouldn’t you like to get fetal blood?’ He liked the idea and
invited me to give a talk there, and that’s how we set up a collaboration. The
first patient they referred for our first intravascular transfusion had five
antibodies with astronomically high titres and the most horrendously hydropic
fetus. These hydropic fetuses are in heart failure. To give a blood transfusion
directly into the fetal circulation was of great concern because there was the
risk of worsening the heart failure and causing fetal death. In fact, it’s quite
remarkable the amount of blood that a fetus will tolerate: you can increase its
feto-placental blood volume by 200 per cent, it will survive. Anyway, this fetus
survived, so we got a steady stream of the most severe patients from Lewisham.
They kept the less severe ones for themselves. We published our earliest
experience in the Lancet in 1981.120
The fetoscopic technique was actually technically very difficult and then by
the mid-1980s Fernand Daffos in Paris had devised an ultrasound-guided
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needling technique of the umbilical cord which was much easier and this
became much more widespread.121 It was taken up in many different parts of
the world, and it led to a rise in further investigation, and treatment. One
could say that it was during this time that fetal medicine was emerging as a
discipline, but it was very much a diagnostic rather than a therapeutic activity,
and the rhesus model gave us an opportunity to develop a therapeutic arm.
Intravascular transfusion was highly successful, and it was most gratifying how,
over and over again, we saw hydropic fetuses in which the hydrops disappeared
and babies were delivered at quite late gestation in very good condition.
Because they all had O-negative blood in their circulation and their own
erythropoeisis had been switched off, they got very little jaundice so that
exchange transfusion almost disappeared. There are fewer and fewer patients
now needing in utero transfusions so we do have problems with maintaining
those skills. On the other hand, the whole area has become much less invasive
than it was. For example, amniocentesis is now no longer needed to assess
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Figure 6: Non-invasive assessment of fetal anaemia by measurement of velocity of fetal blood
in the fetal middle cerebral artery. Top: Doppler image of the fetal head showing the Circle 
of Willis with the Doppler gate on the distal middle cerebral artery. Bottom: Doppler wave
derived from the middle cerebral artery showing a peak systolic velocity of 56.6 cms-1.
severity. We use Doppler ultrasound to investigate the velocity of blood in the fetal
circulation, particularly in the middle cerebral artery (Figure 6), which is inversely
proportional to the haemoglobin level.122 Anaemic fetuses have higher velocities at
which the blood moves, and so we can assess roughly their degree of anaemia, and
then can proceed to blood transfusion, on the basis of this non-invasive test.123
The other very useful recent development is the discovery of free fetal DNA in
maternal blood. That was based on an observation in cancer patients that they
had free DNA in their blood, and then Dennis Lo, in Oxford and now in
Hong Kong, found fetal DNA in maternal plasma.124 This means that one can
detect paternally-inherited genes in the maternal blood. So the fetus of a
rhesus-negative woman can be genotyped from her blood, an advance that
Neil Avent has been involved in as well and on which we have collaborated.
Now that we can genotype the fetus in a much less invasive way, we need
something to block the antigen/antibody interaction, so that we can treat the
fetus without having to resort to transfusion.
Weatherall: Thanks. That was a very stimulating talk. You mean you actually
measure the haemoglobin level in the fetus relatively accurately on the speed
of circulation by ultrasound?
Rodeck: We know the normal range of velocities in the fetal middle cerebral
artery, and if the fetal blood velocity is higher than that, then there is a 90–95
per cent chance that it is anaemic.
Weatherall: How accurate is this?
Rodeck: The detection or the sensitivity is in the region of 90 per cent that the
haemoglobin is below 7g/dl.125
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Weatherall: So there have been extraordinary advances and I suppose you
would argue, historically, that quite a number of them were pushed along by
the rhesus problem.
Rodeck: Yes, indeed. In any case, I think that Liley’s work, both diagnostic and
therapeutic, is a beacon and was way, way ahead of his time. I suppose all of us
have been catching up a bit with the benefit of much better technology. First
of all, the use of ultrasound has enabled invasive procedures to be much safer,
they would be impossible without it, and of course it also now allows us to
avoid some invasive procedures.126
Valaes: Going back to the basics, I would like to stress the importance of being
able to evaluate with reliable antibody tests, like the Coombs test, the presence
of isoimmune haemolytic disease of the newborn. This cleared the field and
enabled us to start looking for other causes of severe neonatal jaundice and
kernicterus – causes like G6PD (glucose 6-phosphate dehydrogenase)
deficiency which in many parts of the world plays as important a role as Rh
incompatibility used to play before effective prevention of isoimmunization.127
Without these tests, we would be still talking about rare antibodies and
unknown blood group antigens to explain these cases. 
Robinson: I would like to ask Charles Rodeck a question. How early now can
you, or would you reckon, to safely do a direct intrauterine transfusion?
Rodeck: We try to avoid it before 20 weeks, because the risks are higher, but
for fetuses that are hydropic at 18 weeks, you have to do something about it
and you can do an intravascular transfusion.
Hunter: I would like to make two points. The first is about the economic and
institutional factors that changed dramatically during Cyril Clarke’s
professional life. From 1936 to 1939, he had a life insurance practice at
Grocer’s Hall in London, EC2, in order to earn his living. With the inception
of the National Health Service in 1948, he had a salary and this gave him a
degree of freedom with which he could pursue original research that has been
discussed today. 
Secondly, I would like to mention that in his presidential address to the
Liverpool Medical Institution in 1970, he spoke about how his original interest
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in inheritance of rhesus blood groups arose from his study of inheritance in
butterflies. His address had the title ‘The Deceptive Way of Life’.128
MacKenzie: Can we mention one other development that has had a very
significant impact upon obstetric practice and neonatal practice, and that is the
introduction of routine antenatal anti-D prophylaxis, which as far as I recall
was introduced initially in the 1970s in Canada by Bowman,129 and Derrick
Tovey130 promoted it here in the early 1980s?131 It’s now almost a statutory
requirement that we provide it for all pregnant rhesus-negative women,
although at the moment I don’t think most units are managing to do that. But
the impact that we have noticed in Oxford since 1986, when we introduced
routine antenatal prophylaxis for all nulliparous rhesus-negative women, has
been considerable. In the 1980s we would see round about ten women a year
in our district, with rhesus D isoimmunization among 5000–6000 women
delivering a year; that proportion of women would be expected with routine
postnatal delivery prophylaxis, with prophylaxis for other precipitating and
potentially sensitizing events during the antenatal period. The figure of
sensitized pregnancies is now down to zero or one per year, as a result of giving
routine antenatal prophylaxis as well as the routine postnatal prophylaxis to all
nulliparous rhesus-negative women. In other words, we have almost
eliminated anti-D isoimmunization in our population. I think it now works
out, when we did our analysis, that there is a 0.3 per cent incidence. Some
cases will always slip through, but I think that does mean, as Professor Rodeck
says, that the number of severely affected cases will diminish throughout the
country, and there probably should only be one or two centres in the UK that
will be treating these severely compromised rhesus pregnancies.
Tovey: There was a major drop in the incidence of anti-D following the
introduction of postnatal anti-D, but from 1975 to 1980 it levelled out,132 and
the incidence of sensitization altered very little over the next few years. This
was primarily due to the fact that there are mothers who were developing
antibodies before delivery. In other words, it was too late for the postnatal anti-D,
and that’s why antenatal prophylaxis was introduced, first of all, by John
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Bowman in Canada.133 The other point is this: when the antibody sensitization
dropped by 70 per cent over that period of time, the death rate of babies
dropped 96 per cent, which showed that not only were anti-D injections helpful
but there was a great improvement in the babies’ antenatal and postnatal care.
It wasn’t only the anti-D injections. We were very successful at saving babies’
lives, but not quite so successful at preventing mothers becoming sensitized.
Therefore, in order to try to do that, we introduced antenatal prophylaxis in this
country, as you know. The work we reported in the Yorkshire trial did show one
thing: it was very important to give antenatal prophylaxis in the first
pregnancy.134 We did not consider it necessary to give anti-D during every
pregnancy, for example, to a woman in her eighth. You can reduce the mortality
considerably by simply just giving it in the first rhesus-positive pregnancy.
Robinson: I want to make a comment, sitting next to this very modest man, that
Dr Derrick Tovey did the first proper antenatal prophylaxis trials.135 Twenty years
ago he started it, and 20 years on they have now decided nationally that it’s a good
thing to do. That very early work was done by Derrick in the Yorkshire trials. 
Tovey: Another point to add. It was done for 2000 mothers and 2000 pregnancies,
and we didn’t get a penny in any way. We did it entirely on our own money!
Dr Mahes de Silva: I wonder if I could ask a question of Professor Rodeck?
There have been reports of intravenous immunoglobulin being effective for the
treatment of very severe Rh disease,136 and with cases getting fewer, has the
need for intervention by transfusion become less?
Rodeck: Yes, there are no randomized trials of high dose IV Ig (intravenous
immunoglobulin) infusions, whether they are given into the mother or indeed
given to the fetus, and personally I have some scepticism that it works for that
particular antigen–antibody interaction. It seems to be of some value for
autoimmune thrombocytopaenia, but again I don’t think there are any
randomized studies that demonstrate that either. 
Weatherall: I would like to thank you for being such a great audience and
taking part so well, and making a chairman’s job so easy. This has been a
marvellous story. I don’t know what the lessons are, except that there was some
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excellent science leading up to it, and then a very unusual man in Liverpool
who was a bit of a polymath with a tremendous flair for picking out bright
young people, as you have seen this afternoon. It seems to me that the concept
of building up a group of young people round such a person, and not pushing
too hard in which direction they go, letting them follow their noses, has proved
a wonderful success in this case. So, although that may not be a message of
enormous help to the government or our health research supporting bodies,
that’s what real life is about, and it’s been a fantastic story. I would like to
congratulate everybody in the field, not just the Liverpool team, but also the
people who have made it possible by the early strategic build up. I’d also like
to thank the Wellcome Trust, and the History of Twentieth Century Medicine
Group for bringing us here this afternoon.
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Dr Alexander Wiener 
FACP (1907–76) was Senior
Serologist to the Office of the
Chief Medical Examiner of NY
City and Head of the Transfusion
Division, The Jewish Hospital of
Brooklyn, NY. Much of his work is
described in Wiener (1954). See
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Professor John Woodrow
FRCP (b. 1924) was on the staff of
the Department of Medicine at the
University of Liverpool between
1961 and 1991, and was
Consultant Physician (General
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(b. 1941) is Professor of Science
and Technology Studies at Virginia
Polytechnic Institute and State
University in Blacksburg, Virginia.
A former laboratory scientist who
has made contributions to cell
biology and linkage testing, she
now conducts research on the
history of genetics and on the
ethical, social and policy issues
related to genetic testing and other
clinical uses of genetics.
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Afibrinogenaemia
A rare disease where the blood has
difficulty clotting due to the lack
of fibrinogen, or clotting factor I.
Amniocentesis
A procedure in which a needle is
passed transabdominally into the
amniotic sac to obtain a sample of
amniotic fluid. The optical density
of the fluid is measured to give an
assessment of the degree of fetal
haemolysis (the rate of red blood
cell destruction, caused by the
rhesus antibodies).
Amniotic fluid
The fluid surrounding the
developing fetus, found within the
amniotic sac contained in the
mother’s uterus.
Bilirubin
The orange-yellow pigment of bile,
the fluid that aids digestion and is
secreted by the liver.
Contig
A set of overlapping segments 
of DNA.
Disseminated intravascular
coagulation (DIC)
Intravascular coagulation where
many coagulation factors are
depleted. It can be induced by
different factors including infection
in the blood by bacteria or fungus,
severe tissue injury as in burns and
head injury, cancer, reactions to
blood transfusions, and obstetrical
complications such as retained
placenta after delivery. See also
afibrinogenaemia.
Erythroblastosis fetalis
Severe anaemia in newborn babies;
the result of Rh incompatibility
between maternal and fetal blood
which typically occurs when the
child of an Rh-negative mother
inherits Rh-positive blood from the
father. This can be diagnosed
before birth by amniocentesis.
Friedreich ataxia
A hereditary disease in which there
is degeneration of the nerves in the
spinal cord, the cerebellum and of
sensory nerves to the hands and
feet. It starts in childhood or
adolescence, marked by an
unsteady gait and an inability to
coordinate voluntary movements.
Haemolytic disease of newborn
(HDN) (rhesus disease)
The condition caused by Rh-
positive cells from a fetus with a
Rh-positive father finding their
way into the circulation of a Rh-
negative mother, usually at birth,
and inducing antibody formation
Glossary
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to what is, for her, a foreign
antigen. In the next pregnancy her
antibodies are transferred to the
fetus across the placenta (a normal
protective process) and attack the
baby’s red blood cells if they are Rh
positive, inducing haemolysis and
causing anaemia and jaundice.
This sequence of events can be
prevented by giving women
antibodies to Rh-positive cells at
delivery, thus preventing her
sensitization. Some cases of
haemolytic disease result from
maternal transfer of naturally
occurring antibody to her fetus,
such as may occur with an A or B
group fetus and an O group
mother. See also kernicterus.
Hydrops fetalis
Oedema of the entire body due to
abnormal accumulation of serous
fluid in the tissues, associated with
severe anaemia and occurring in
fetal erythroblastosis.
Kernicterus
Kernicterus may occur when there
is a high level of unconjugated
bilirubin in the circulating blood
such as in haemolytic disease of
the newborn, but much more
commonly in premature babies
who tend to have a deficiency of
liver enzymes for conjugation of
bilirubin. High levels of
unconjugated bilirubin can pass
the immature blood-brain barrier
of the newborn and cause
degeneration of cells of the basal
ganglia and hippocampus resulting
in seizure, cerebral palsy and in
severe cases death.
Jaundice
A condition caused by obstruction
of the bile and accumulation of
bile pigment (bilirubin) and
characterized by yellowing of the
skin and whites of the eyes.
Peritoneum
A transparent membrane that lines
the abdominal cavity in mammals
and covers most of the viscera.
Petechiae 
Pinpoint-sized haemorrhages of
small capillaries in the skin or
mucous membranes.
Plasmapheresis
The procedure whereby plasma is
removed, separated and extracted
from anticoagulated whole blood
and the remaining red blood cells
are returned to the patient.
Preterm (premature) birth
The birth of a baby before 37
weeks of gestation (calculated from
the first day of the mother’s last
menstrual period). Very preterm is
birth before 33 weeks.
Rhesus (Rh) factor
A blood protein that may cause
severe complications in pregnancy.
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People without Rh factor are
known as Rh negative (or RhD
negative), while people with the
Rh factor are Rh positive (or RhD
positive). If a woman who is Rh
negative is pregnant with a fetus
that is Rh positive, her body may
make antibodies against the fetus’s
blood. This can cause Rh disease,
also known as haemolytic disease
of the newborn, in the baby.
Sagittal sinus
A large vein that goes over the top
of the skull from front to back and
then splits to take blood from the
brain back toward the heart.
Thrombocytopaenia
A deficiency of platelets often
associated with haemorrhage.
Trimester
A period of three months. During
pregnancy, the first trimester
continues until week 13, the
second trimester from week 13 to
28, and the third trimester from
week 28 until delivery.
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